var title_f30_6_30816="AML FAB M2";
var content_f30_6_30816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute myeloid leukemia (M2)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with AML (FAB classification M2). (Wright-Giemsa stain). The WBC count was 70,000/ L and was comprised almost entirely of myeloblasts with numerous azurophilic granules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30816=[""].join("\n");
var outline_f30_6_30816=null;
var title_f30_6_30817="Cumulus oophorus";
var content_f30_6_30817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cumulus oophorus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasonography of an ovary near the end of the follicular phase of the menstrual cycle. The red arrow points to the dissociating cumulus oophorus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Judith Adams, DMU.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30817=[""].join("\n");
var outline_f30_6_30817=null;
var title_f30_6_30818="Erythromycin (topical): Pediatric drug information";
var content_f30_6_30818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erythromycin (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?30/28/31171?source=see_link\">",
"    see \"Erythromycin (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/47/756?source=see_link\">",
"    see \"Erythromycin (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8086237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Akne-mycin&reg;;",
"     </li>",
"     <li>",
"      Ery",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8086238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sans Acne&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10484228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Macrolide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10485148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/28/31171?source=see_link\">",
"      see \"Erythromycin (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Apply 2% solution over the affected area twice daily after the skin has been thoroughly washed and patted dry",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8086447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 2% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Akne-mycin&reg;: 2% (25 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pledget, topical: 2% (60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ery: 2% (60s) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 2% (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8086240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes ointment",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10485149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply thin film to the cleansed, affected area.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10485144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acne vulgaris",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8085307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Erythromycin may be confused with azithromycin, clarithromycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8086296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Dermatologic: Erythema, desquamation, dryness, pruritus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10485145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to erythromycin or any component",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8086299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8086242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9793457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Erythromycin has been shown to cross the placenta following oral dosing. Refer to the Erythromycin (Systemic) monograph for details. The amount of erythromycin available systemically following topical application is considered to be very low. Systemic absorption would be required in order for erythromycin to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10485147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15978 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30818=[""].join("\n");
var outline_f30_6_30818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086237\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086238\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484228\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485148\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086447\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086240\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485149\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485144\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085307\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086296\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485145\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299282\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086299\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086242\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9793457\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485147\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15978\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15978|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26419?source=related_link\">",
"      Erythromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/61/4052?source=related_link\">",
"      Erythromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/41/42642?source=related_link\">",
"      Erythromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/6/25705?source=related_link\">",
"      Erythromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/23/22901?source=related_link\">",
"      Erythromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/32/22025?source=related_link\">",
"      Erythromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/28/31171?source=related_link\">",
"      Erythromycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/47/756?source=related_link\">",
"      Erythromycin (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_6_30819="Mouth and dental injuries in children";
var content_f30_6_30819=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Mouth and dental injuries in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/6/30819/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30819/contributors\" id=\"au5592\">",
"       Dennis J McTigue, DDS",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30819/contributors\" id=\"au2826\">",
"       Amy Thompson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/6/30819/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30819/contributors\" id=\"se5035\">",
"       Ann Griffen, DDS, MS",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30819/contributors\" id=\"se154\">",
"       Richard G Bachur, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/6/30819/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30819/contributors\" id=\"de2105\">",
"       James F Wiley, II, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/6/30819?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Nearly 50 percent of children will have some type of injury to a tooth during childhood, many of which are preventable. Mouth injuries are also common. Tooth and mouth injuries often occur after a fall, sports injury, or fight.",
"    </p>",
"    <p>",
"     In most cases, tooth and mouth injuries are not life threatening. Rarely, a child may develop serious complications. Injuries to the teeth and mouth can also have long-lasting effects on the child's appearance and self confidence.",
"    </p>",
"    <p>",
"     This topic will review the most common causes, evaluation, and treatment of dental and mouth injuries, including when to seek medical attention. A topic that discusses head injury in children is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/44/14020?source=see_link\">",
"      \"Patient information: Head injury in children and adolescents (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Falls, sports-related injuries, and fights are the most common causes of tooth injury in children. Mouth injuries can also occur when a child trips or is pushed with an object in the mouth.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      EVALUATION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many parents wonder if their child should receive medical attention after a dental or mouth injury. Children with any of the following symptoms should be evaluated by a healthcare provider. Depending upon the particular circumstances, this may be done over the phone, at the pediatrician's or dentist's office, or in an emergency department:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If there is pain, tenderness, or sensitivity (to",
"       <span class=\"nowrap\">",
"        hot/cold",
"       </span>",
"       or pressure) in a tooth",
"      </li>",
"      <li>",
"       If there is a broken, loose, or missing tooth after trauma (the tooth could have been inhaled or swallowed)",
"      </li>",
"      <li>",
"       If there is bleeding that does not stop after applying pressure for 10 minutes",
"      </li>",
"      <li>",
"       If there is pain in the jaw when opening or closing the mouth",
"      </li>",
"      <li>",
"       If there is difficulty swallowing or breathing",
"      </li>",
"      <li>",
"       If there is an object stuck in the roof of the mouth, cheek, tongue, or throat (do NOT remove the object)",
"      </li>",
"      <li>",
"       If there is a large or gaping cut inside the mouth or on the face",
"      </li>",
"      <li>",
"       If the child could have a puncture in the back of the throat",
"      </li>",
"      <li>",
"       If there is a cut on the lip that extends through the lip's border into the surrounding skin",
"      </li>",
"      <li>",
"       If the child is weak, numb, or has blurred vision or slurred speech",
"      </li>",
"      <li>",
"       If the parent is concerned about the child's condition",
"      </li>",
"      <li>",
"       If the child develops a fever (temperature",
"       <span class=\"nowrap\">",
"        &ge;100.4&ordm;F/38&ordm;C)",
"       </span>",
"       or other signs of infection after a mouth or tooth injury (localized redness, pus, increasing pain); signs of more serious infection may include neck pain or stiffness, inability to open the mouth completely, drooling, or chest pain.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Medical history and physical examination",
"     </span>",
"     &nbsp;&mdash;&nbsp;The parent or child should try to describe how the injury occurred. If there is any reason to suspect that another adult or child intentionally injured the child, this should be discussed with the healthcare provider.",
"    </p>",
"    <p>",
"     During the physical examination, the clinician will examine the child's mouth, throat, head, neck, and body.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Depending upon the injury, some children will need an imaging test (x-ray, CT scan, MRI). The imaging test can help to determine if there are fractures in a bone, damage to the root of a tooth, damage to a blood vessel, or if the child has swallowed or inhaled a foreign body (ie, a piece of a tooth). Not every child with a dental or mouth injury will require an imaging test.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Dental injuries",
"     </span>",
"     &nbsp;&mdash;&nbsp;The treatment for dental injuries depends upon the type of injury and whether the injured tooth is a primary (baby) or permanent (adult) tooth.",
"    </p>",
"    <p>",
"     Parents often wonder if a child's permanent or primary teeth were injured. Permanent teeth are not usually present before six to seven years of age. Primary teeth look different than permanent teeth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Dislocated or loose primary tooth",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common injury to the primary teeth is dislocation of the front teeth. The management of these injuries focuses on preventing future damage to the permanent teeth.",
"    </p>",
"    <p>",
"     A primary tooth that is loose may be left in place or removed, depending upon the severity of the injury. In many cases, a loose tooth will heal without treatment. Injured teeth that are very loose may need to be removed if there is a possibility that the tooth could fall out easily or cause the child to choke (eg, while sleeping).",
"    </p>",
"    <p>",
"     If the primary tooth was knocked out completely, it should not be placed back into the gums because of the risk of damage to the permanent tooth to follow. Losing a primary tooth early does not typically affect the child's speech or the position of the permanent tooth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Broken primary tooth",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children with broken teeth should see a dentist promptly. The dentist will determine if the tooth's nerves or blood vessels could be damaged. Treatment may include smoothing the rough edges of the tooth, repairing it with a tooth-colored resin material, leaving the tooth in place, or removing it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Dislocated permanent tooth",
"     </span>",
"     &nbsp;&mdash;&nbsp;A permanent tooth that is knocked out is a dental emergency that requires prompt treatment. The tooth should be placed back into the tooth socket as soon as possible, ideally within 15 minutes and up to one hour (or longer if stored in cold milk). At least 85 percent of teeth that are put back in the tooth socket within five minutes survive, compared to very few teeth that are stored dry and reimplanted after one hour [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/6/30819/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Because of the importance of replacing the tooth quickly, the child, parent, or another adult can (and should) attempt to reimplant the tooth. The following steps are recommended:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Handle the tooth carefully by the top (crown) (",
"       <a class=\"graphic graphic_picture graphicRef64461 \" href=\"mobipreview.htm?29/8/29839\">",
"        picture 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Remove any debris by gentle rinsing the tooth with saline or tap water; the tooth should not be scrubbed or sterilized.",
"      </li>",
"      <li>",
"       Place the tooth by hand back into the socket.",
"      </li>",
"      <li>",
"       Keep the tooth in place by having the child bite on a clean towel.",
"      </li>",
"      <li>",
"       The child should see a dentist for treatment as soon as possible.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If it is not possible to replace the tooth in the gums, the tooth should be stored in a container of cold milk. If cold milk is not immediately available then place the tooth in a container of the child's saliva. Do",
"     <strong>",
"      not",
"     </strong>",
"     store the tooth in water or saline, because this will reduce the chances of successfully healing of the reimplanted tooth. The child should see a dentist or other healthcare provider as soon as possible to reimplant the tooth. The likelihood that the tooth will survive is reduced the longer the tooth is out of the mouth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Loose permanent tooth",
"     </span>",
"     &nbsp;&mdash;&nbsp;A loose permanent tooth is also a dental emergency that requires prompt treatment. In most cases, the tooth can be returned to its correct position and monitored over time. However, it may be necessary to use anesthesia (to prevent pain) and stitches or splints (to hold the tooth in place). A dentist with experience in treating dental injuries in children is the best person to evaluate and treat children with loose permanent teeth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Broken permanent tooth",
"     </span>",
"     &nbsp;&mdash;&nbsp;Broken permanent teeth can usually be repaired successfully. For the best possible outcome, the child should see a dentist for treatment within two days from the time of the injury. Broken teeth that are sensitive to hot or cold need to be treated urgently. Tooth fragments should be saved, if possible, and stored in tap water as they can sometimes be reattached. If tooth fragments cannot be found or cannot be reattached, the tooth may be repaired with a material called composite resin, which can be matched to the color of the natural tooth.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Mouth injuries",
"     </span>",
"     &nbsp;&mdash;&nbsp;The evaluation and management of mouth injuries depends upon how the injury happened, what areas are injured, and the severity of the injury.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Tears",
"     </span>",
"     &nbsp;&mdash;&nbsp;Small wounds or tears of the mouth usually do not require stitches. Tears of the flap of skin under the upper lip (the frenulum) also heal without stitches.",
"    </p>",
"    <p>",
"     Cuts to the tongue that are large, especially if near the tip of the tongue, may require stitches. Wounds that involve the outer part of the lips and extend into the skin also frequently require stitches [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/6/30819/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Puncture wounds",
"     </span>",
"     &nbsp;&mdash;&nbsp;Wounds to the back of the throat can occur if a child falls while holding a pencil, toothbrush, or other object. If the object penetrates the side of the back of the throat, near the tonsils, there is a risk of injury to the carotid artery (a large blood vessel). A child with this type of injury may require an imaging test",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     evaluation by a surgeon, and will sometimes require hospitalization or surgery [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/6/30819/abstract/3\">",
"      3",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23016?source=see_link\">",
"      \"Oropharyngeal trauma in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Home management of minor mouth injuries",
"     </span>",
"     &nbsp;&mdash;&nbsp;Minor injuries to the mouth often bleed, which can be frightening for a child. To stop bleeding inside the lip, press the area against the teeth and hold for several minutes. To stop bleeding of the tongue, hold the injured area between the fingers with a piece of gauze or a clean cloth. Applying pressure should control the bleeding within 10 minutes. It is normal to have small amounts of blood-tinged saliva afterwards.",
"    </p>",
"    <p>",
"     Small mouth wounds usually heal within three days. The area may appear pale or whitened; this is normal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Pain relief",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a child has pain related to a mouth or tooth injury, the child may apply a piece of ice or frozen popsicle to the area. A non-prescription pain medication, such as ibuprofen (Advil&reg;, Motrin&reg;) or acetaminophen (Tylenol&reg;) may also be given. These medications should be dosed according to the child's weight rather than age.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antibiotics are not often required for children with dental or mouth injuries. However, children with complicated mouth wounds, including those that require stitches, may be treated with five to seven days of antibiotics to prevent infection [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/6/30819/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Tetanus prevention",
"     </span>",
"     &nbsp;&mdash;&nbsp;A dose of tetanus vaccine may be recommended if the child has not had their booster dose (generally given at age 11 to 12 years) or if their last dose was given more than five years ago. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"      \"Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=see_link\">",
"      \"Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Hygiene and diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;After a tooth or mouth injury, it is important to continue keeping the teeth clean. This includes brushing twice per day and flossing once per day. Occasionally, a mouthwash will be prescribed to prevent swelling and infection.",
"    </p>",
"    <p>",
"     If a child's tooth is loose or the mouth is sore, a soft diet is recommended for several days. Children who have stitches in the mouth should avoid spicy or salty food, popcorn, and straws for approximately one week.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      POTENTIAL COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Most children recover completely from mouth and dental injuries without complications. However, prompt treatment and regular follow up will help to ensure the best possible outcome.",
"    </p>",
"    <p>",
"     In a small number of cases, complications can occur, including:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Damage to the permanent teeth",
"       </strong>",
"       &ndash; This may include discoloration of the tooth, complete loss of the tooth, or sensitivity to",
"       <span class=\"nowrap\">",
"        heat/cold.",
"       </span>",
"       Children who have a permanent tooth successfully replaced in the socket will often require a root canal and placement of a crown in the future.",
"      </li>",
"      <li>",
"       <strong>",
"        Scarring",
"       </strong>",
"       &ndash; Wounds to the lip, especially those that cross into the skin, may heal with a scar. Tears of the tongue that do not heal properly can affect speech and swallowing.",
"      </li>",
"      <li>",
"       <strong>",
"        Infection",
"       </strong>",
"       &ndash; This may include infection of the teeth, gums, and deep spaces of the neck and chest (which contain vital structures, such as the carotid artery and trachea).",
"      </li>",
"      <li>",
"       <strong>",
"        Excessive bleeding",
"       </strong>",
"       &ndash; This complication is not common, but may occur if there is injury of a major blood vessel.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     One of the ways that parents can reduce the chances of mouth and dental injuries during recreational and sports activities is to have the child wear a mouthguard.",
"    </p>",
"    <p>",
"     Mouth injuries can be prevented by teaching children not to put anything except food or drinks in their mouth. It is also important that children learn to sit while eating and drinking, particularly while using a straw or eating food on a stick (eg, popsicles, lollipops). Eating in the car can also lead to injuries, especially if the child is in a seat where an airbag could deploy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Mouthguards",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mouthguards can significantly reduce the risk of mouth injuries and the incidence of concussion and jaw fracture in athletes. The American Dental Association (ADA) and the Academy for Sports Dentistry (ASD) recommend properly fitted mouthguards for a variety of recreational activities and sports that place participants at risk for oral injury (",
"     <a class=\"graphic graphic_table graphicRef68070 \" href=\"mobipreview.htm?30/17/31003\">",
"      table 1",
"     </a>",
"     )&nbsp;[",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/6/30819/abstract/5\">",
"      5",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     There are three main types of mouthguards:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Stock mouthguards fit loosely over the upper teeth; they are not individually shaped. Stock mouthguards may interfere with breathing and speech because the wearer must hold the upper and lower teeth together to prevent the guard from moving.",
"      </li>",
"      <li>",
"       Self-adapted mouthguards, also known as \"boil and bite\" mouthguards, can be individually shaped. The wearer heats the guard in boiling water and bites into the warmed plastic for a customized fit. Self-adapted mouthguards are moderately priced and usually stay in place. However, they are subject to bite-through problems and are not as strong as custom-made mouthguards over time.",
"      </li>",
"      <li>",
"       Custom-made mouthguards are made by a dentist. The dentist takes an impression of the athlete's mouth with a material that hardens, then forms plastic around the hardened impression. Custom-made mouthguards provide better protection, are more comfortable, and are more likely to stay in the mouth compared to other models. However, they may be more expensive than some athletes can afford. Self-adapted mouthguards are a reasonable alternative in this case.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Mouthguards should be stored in a plastic protective container. They should be regularly inspected for distortion, bite-through, and tears. They should be rinsed with water before use and washed after each use in cold or lukewarm water. They also may be cleaned with toothpaste and a soft-bristle toothbrush and rinsed with mouthwash. Daily washing minimizes build-up of saliva, bacteria, and debris.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413480966\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5518710\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/52/34626?source=see_link\">",
"      Patient information: Mouth and dental injuries in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5518718\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/44/14020?source=see_link\">",
"      Patient information: Head injury in children and adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/36/42566?source=see_link\">",
"      Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/18/37156?source=see_link\">",
"      Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/46/32489?source=see_link\">",
"      Evaluation and management of dental injuries in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24309?source=see_link\">",
"      Evaluation and repair of tongue lacerations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23016?source=see_link\">",
"      Oropharyngeal trauma in children",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Nemours Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/parent/firstaid_safe/emergencies/tooth_injury.html\">",
"      file://kidshealth.org/parent/firstaid_safe/emergencies/tooth_injury.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Dental Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ada.org/2970.aspx?currentTab=1\">",
"      file://www.ada.org/2970.aspx?currentTab=1",
"     </a>",
"     , also available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Columbia University School of Dental Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.simplestepsdental.com/SS/ihtSS/r.WSIHW000/st.32579/t.32606/pr.3.html\">",
"      www.simplestepsdental.com/SS/ihtSS/r.WSIHW000/st.32579/t.32606/pr.3.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/6/30819/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/6/30819?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30819/abstract/1\">",
"      Flores MT, Malmgren B, Andersson L, et al. Guidelines for the management of traumatic dental injuries. III. Primary teeth. Dent Traumatol 2007; 23:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30819/abstract/2\">",
"      Lamell CW, Fraone G, Casamassimo PS, Wilson S. Presenting characteristics and treatment outcomes for tongue lacerations in children. Pediatr Dent 1999; 21:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30819/abstract/3\">",
"      Randall DA, Kang DR. Current management of penetrating injuries of the soft palate. Otolaryngol Head Neck Surg 2006; 135:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30819/abstract/4\">",
"      Mark DG, Granquist EJ. Are prophylactic oral antibiotics indicated for the treatment of intraoral wounds? Ann Emerg Med 2008; 52:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30819/abstract/5\">",
"      ADA Council on Access, Prevention and Interprofessional Relations, ADA Council on Scientific Affairs. Using mouthguards to reduce the incidence and severity of sports-related oral injuries. J Am Dent Assoc 2006; 137:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30819/abstract/6\">",
"      Andreasen JO, Borum MK, Jacobsen HL, Andreasen FM. Replantation of 400 avulsed permanent incisors. 4. Factors related to periodontal ligament healing. Endod Dent Traumatol 1995; 11:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30819/abstract/7\">",
"      McIntyre JD, Lee JY, Trope M, Vann WF Jr. Management of avulsed permanent incisors: a comprehensive update. Pediatr Dent 2007; 29:56.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_6_30819=[""].join("\n");
var outline_f30_6_30819=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           POTENTIAL COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/8/29839\" title=\"picture 1\">",
"           Dislocated tooth PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/17/31003\" title=\"table 1\">",
"           Sports mouthguard PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_6_30820="U-S choriocarcinoma and AVM B";
var content_f30_6_30820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64599&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound choriocarcinoma and AVM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Choriocarcinoma with associated arteriovenous malformation: Patient with choriocarcinoma and associated AVM. Color Doppler of the complex lesion in the myometrium reveals a large amount of swirling blood flow consistent with arterial-venous fistula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Department of Radiology, Santa Clara Valley Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30820=[""].join("\n");
var outline_f30_6_30820=null;
var title_f30_6_30821="Permethrin: Patient drug information";
var content_f30_6_30821=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Permethrin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/22/28004?source=see_link\">",
"     see \"Permethrin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/20/23875?source=see_link\">",
"     see \"Permethrin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A200&reg; Lice [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Complete Lice Treatment System [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Creme Rinse Lice Treatment [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Creme Rinse [OTC];",
"     </li>",
"     <li>",
"      Nix&reg; Lice Control Spray [OTC];",
"     </li>",
"     <li>",
"      Rid&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kwellada-P&trade;;",
"     </li>",
"     <li>",
"      Nix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat scabies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use the lotion on infants younger than 2 months of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702719",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to permethrin, chrysanthemums, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor. You may have a chance of a very bad infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching. Talk to the doctor about what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Scalp irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699106",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A burning or tingling feeling that is not normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        Do not use on people or animals.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For use on non-washable items only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray on infested part and let dry all the way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vacuum rugs and carpets. Throw away vacuum cleaner bags after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All other products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to take this drug as you have been told by your doctor. Do not use more than you were told to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash all bedding, towels, and recently worn clothes in hot water or have them dry cleaned.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cream:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the skin from the neck to the toes. Put in the skin folds, creases, and spaces between the fingers and toes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694527",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put under fingernails.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696155",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trim fingernails short.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694450",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put cream under nails with a toothbrush. Throw away toothbrush after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear light clothing while this drug is on your skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not let your skin touch anyone else's skin while wearing the cream.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After 8 to 14 hours, fully wash cream from skin using warm, soapy water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705358",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cream rinse and lotion:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shampoo hair, rinse, and towel dry before use. Use a shampoo without a conditioner.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694461",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lightly coat hair and scalp.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Work into hair and scalp gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave on for 10 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not cover head while cream rinse or lotion is on hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694386",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After 10 minutes, put a little bit of warm water on hair and lather.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse fully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696254",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694829",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry with a towel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use special nit comb or tweezers to get rid of dead nits (lice eggs) from hair.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Throw away any part not used after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11514 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30821=[""].join("\n");
var outline_f30_6_30821=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208544\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208545\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026032\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026031\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026036\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026037\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026039\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026034\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026035\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026040\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026041\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/22/28004?source=related_link\">",
"      Permethrin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/20/23875?source=related_link\">",
"      Permethrin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_6_30822="Cesarean scar preg A";
var content_f30_6_30822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74141%7EOBGYN%2F79054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74141%7EOBGYN%2F79054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cesarean scar pregnancy at 6 weeks - transabdominal ultrasonography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image shows a retroflexed uterus (U) with gestational sac (arrow) deforming the bladder (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cesarean scar pregnancy at 6 weeks - transvaginal ultrasonography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Image shows the gestational sac (arrow) without surrounding myometrium. Note the empty endometrial cavity (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30822=[""].join("\n");
var outline_f30_6_30822=null;
var title_f30_6_30823="Approach to the child with out-toeing";
var content_f30_6_30823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with out-toeing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30823/contributors\">",
"     Scott B Rosenfeld, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30823/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30823/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30823/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/6/30823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H141828000\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In-toeing (&ldquo;pigeon-toeing&rdquo;) is a rotational variation of the lower extremity where the feet or toes point toward the midline during gait (",
"    <a class=\"graphic graphic_figure graphicRef75796 \" href=\"mobipreview.htm?17/13/17616\">",
"     figure 1",
"    </a>",
"    ). Out-toeing is a rotational variation of the lower extremity where the feet or toes point away from the midline during gait (",
"    <a class=\"graphic graphic_figure graphicRef75796 \" href=\"mobipreview.htm?17/13/17616\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In-toeing and out-toeing are among the most common anatomic musculoskeletal variations encountered by pediatric primary care providers and a frequent reason for referral to a pediatric orthopedic surgeon. However, most children with in-toeing or out-toeing have variations of normal lower-extremity development that will improve spontaneously and can be monitored by the primary care provider.",
"   </p>",
"   <p>",
"    An understanding of the normal growth and development of the lower extremity is essential in evaluating a child&rsquo;s rotational alignment and helps to elucidate the mechanism of out-toeing. The most common causes of out-toeing in children are external rotation contracture of the hip, external tibial torsion, and femoral retroversion. These rotational variations are seen in normal, healthy children, and rarely persist into adolescence. Although out-toeing rarely causes dysfunction, out-toeing due to persistent external tibial torsion may be associated with patellofemoral pain. History and examination generally are sufficient to distinguish common rotational variations from less common pathologic causes of in-toeing and out-toeing (eg, hemiplegic cerebral palsy). (See",
"    <a class=\"local\" href=\"#H141830452\">",
"     'Evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will provide an overview of lower-extremity rotational development, common causes of out-toeing, pathologic causes of out-toeing that must be excluded, and an approach to the evaluation and management of the child with out-toeing. In-toeing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42264?source=see_link\">",
"     \"Approach to the child with in-toeing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141828373\">",
"    <span class=\"h1\">",
"     NORMAL PHYSIOLOGIC ALIGNMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational alignment of the lower extremity is determined by the alignment of the foot, the rotation of the tibia in relation to the transcondylar axis of the femur (tibial torsion), and the rotation of the neck of the femur in relation to the transcondylar axis of the femur (femoral anteversion) (",
"    <a class=\"graphic graphic_figure graphicRef56825 \" href=\"mobipreview.htm?25/33/26129\">",
"     figure 2",
"    </a>",
"    ). In-toeing and out-toeing may be accentuated between six months and five years, when children are developing their walking and coordination skills [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/1\">",
"     1",
"    </a>",
"    ]. Normal growth and improved coordination typically lead to spontaneous resolution of rotational variations (",
"    <a class=\"graphic graphic_table graphicRef64901 \" href=\"mobipreview.htm?13/4/13387\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Intrauterine positioning has an important influence on the rotational alignment of the legs. At the seventh week of gestation, the lower limb rotates medially (internally), followed by external (lateral) rotation of the upper leg. For the remainder of gestation, the tibiae and feet are medially (internally) rotated, and the hips and femora are laterally (externally) rotated, resulting in an external rotation contracture at the hip joint (",
"    <a class=\"graphic graphic_figure graphicRef79381 \" href=\"mobipreview.htm?36/62/37858\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal newborn posture reflects intrauterine positioning. The hips are flexed and externally rotated, with the patellae pointing outward. The tibiae and feet remain relatively internally rotated, but this is overshadowed by the external rotation contracture at the hip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/3\">",
"     3",
"    </a>",
"    ]. Out-toeing due to external rotation contracture of the hip usually resolves by the time the child begins walking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141829701\">",
"    <span class=\"h1\">",
"     COMMON CAUSES OF OUT-TOEING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of out-toeing are external rotation contracture of the hip, external tibial torsion, and femoral retroversion (",
"    <a class=\"graphic graphic_table graphicRef80335 \" href=\"mobipreview.htm?6/15/6397\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141829708\">",
"    <span class=\"h2\">",
"     External rotation contracture of the hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal intrauterine position of flexed and externally rotated hips results in an external rotation contracture of the hips. This causes out-toeing when the young child is lying down as well as when he or she begins to stand and walk. When combined with physiologic tibia vara, hip external rotation contracture may accentuate the appearance of bowed legs. External rotation contracture of the hip is typically bilateral and symmetrical.",
"   </p>",
"   <p>",
"    Characteristic examination features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral and symmetrical out-toeing",
"     </li>",
"     <li>",
"      When standing and walking both the patella and feet point away from the midline (external foot progression angle and external patella progression angle) (see",
"      <a class=\"local\" href=\"#H141830473\">",
"       'Observation of gait'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Increased hip external rotation compared with internal rotation (see",
"      <a class=\"local\" href=\"#H141830480\">",
"       'Focused examination of the lower extremities'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Out-toeing due to external hip rotation contracture usually resolves around 12 months of age when the child begins to walk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/5\">",
"     5",
"    </a>",
"    ]. The management of external rotation contracture of the hip is discussed below. (See",
"    <a class=\"local\" href=\"#H141831309\">",
"     'External rotation contracture of the hip'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141829715\">",
"    <span class=\"h2\">",
"     External tibial torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;External tibial torsion is likely a result of intrauterine positioning but is usually discovered in late childhood (four to seven years of age) or early adolescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6\">",
"     6",
"    </a>",
"    ]. It may be more common in preterm infants secondary to prone positioning in the neonatal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/7\">",
"     7",
"    </a>",
"    ]. It is often unilateral and is more common on the right side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristic examination features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When standing and walking the foot points outward relative to the patella (external foot progression angle) (see",
"      <a class=\"local\" href=\"#H141830473\">",
"       'Observation of gait'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      The medial malleolus is anterior to the lateral malleolus (with the child seated with the thigh directly in front of the hip joint and the knee pointed straight ahead) (see",
"      <a class=\"local\" href=\"#H141830480\">",
"       'Focused examination of the lower extremities'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      In the prone position the thigh foot angle is external (",
"      <a class=\"graphic graphic_figure graphicRef68556 \" href=\"mobipreview.htm?34/22/35169\">",
"       figure 4",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H141830480\">",
"       'Focused examination of the lower extremities'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since normal development of the tibia causes external rotation, external tibial torsion often does not improve spontaneously and out-toeing due to external tibial torsion may worsen over time. Despite this, external tibial torsion rarely causes pain or functional abnormalities. Problems associated with external tibial torsion may include difficulty in parallel skiing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/8\">",
"     8",
"    </a>",
"    ], patellofemoral instability, and patellofemoral pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/9\">",
"     9",
"    </a>",
"    ]. Knee pain from external tibial torsion is most common when associated with increased femoral anteversion (also known as &ldquo;miserable malalignment&rdquo;, &ldquo;torsional malalignment syndrome&rdquo;, or &ldquo;malignant malalignment syndrome&rdquo;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6,10,11\">",
"     6,10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=see_link&amp;anchor=H8#H8\">",
"     \"Patellofemoral pain syndrome\", section on 'Malalignment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141829722\">",
"    <span class=\"h2\">",
"     Femoral retroversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral retroversion is a rare cause of out-toeing. It is associated with increased external rotation and decreased internal rotation at the hip joint. It is more commonly observed in obese children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6\">",
"     6",
"    </a>",
"    ]. Characteristic examination features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral and symmetrical out-toeing",
"     </li>",
"     <li>",
"      External foot and patella progression angles (see",
"      <a class=\"local\" href=\"#H141830473\">",
"       'Observation of gait'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Increased hip external rotation compared with internal rotation (see",
"      <a class=\"local\" href=\"#H141830480\">",
"       'Focused examination of the lower extremities'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Femoral retroversion may be associated with osteoarthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/12\">",
"     12",
"    </a>",
"    ], stress fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/13\">",
"     13",
"    </a>",
"    ], and slipped capital femoral epiphysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141829729\">",
"    <span class=\"h1\">",
"     UNCOMMON PATHOLOGIC CAUSES OF OUT-TOEING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncommon, pathologic causes of out-toeing may include slipped capital femoral epiphysis (SCFE), Legg-Calv&eacute;-Perthes disease (LCP, idiopathic osteonecrosis of the hip), and neuromuscular disorders. Although these etiologies are uncommon, they must be considered in the evaluation of a child with out-toeing because they do not resolve spontaneously and may result in long term disability. They can generally be excluded through history, physical examination, and radiographs.",
"   </p>",
"   <p>",
"    Developmental hip disorders may present with out-toeing gait. SCFE and LCP may result in proximal femoral deformity causing a derangement in hip rotation. Children with SCFE or LCP most commonly have limited hip internal rotation. They may present with pain in the hip, thigh, or knee with a limp and unilateral out-toeing. Examination may demonstrate painful range of motion of the hip with decreased internal rotation and increased external rotation. Anteroposterior and frog leg (lateral) pelvis radiographs should be obtained in children with suspected SCFE or LCP. Referral to an orthopedic surgeon is also warranted in such children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16729?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of hip pain in childhood\", section on 'Legg-Calv&eacute;-Perthes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild hemiplegic cerebral palsy rarely may present with an out-toeing gait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/15\">",
"     15",
"    </a>",
"    ]. Spasticity secondary to cerebral palsy may result in over-pull of the evertors of the foot, which may cause an asymmetric, unilateral out-toeing gait. Asymmetry is a red flag. The history may reveal perinatal problems or abnormal developmental milestones. Examination may demonstrate spasticity of the gastro-soleus, hamstrings, peroneal muscles, and hip adductors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/16\">",
"     16",
"    </a>",
"    ]. Such findings should prompt referral to a specialist (eg, neurologist, physical medicine and rehabilitation specialist) for evaluation for cerebral palsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features of cerebral palsy\", section on 'Spastic hemiplegia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4104?source=see_link&amp;anchor=H22#H22\">",
"     \"Diagnosis and classification of cerebral palsy\", section on 'Summary and recommendations'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141830149\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting complaints for a child with out-toeing may include concerns about appearance of the legs or foot, excessive falling, awkward running style, and uneven shoe wear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141830452\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The objectives of the evaluation are to identify parental concerns (eg, cosmesis, frequent falling, permanent disability, interference with sports performance), identify the cause of out-toeing, and exclude pathologic etiologies. The history and physical examination usually are sufficient to achieve these goals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141830459\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Birth history, including gestational age and complications (prematurity may be a clue to cerebral palsy or external tibial torsion).",
"     </li>",
"     <li>",
"      Developmental milestones (delayed milestones may be a clue to cerebral palsy).",
"     </li>",
"     <li>",
"      Early hand preference (preference for one side before three years of age may be a sign of hemiplegia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4104?source=see_link&amp;anchor=H8#H8\">",
"       \"Diagnosis and classification of cerebral palsy\", section on 'Spastic hemiplegia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Family history out-toeing (femoral retroversion and external tibial torsion run in families); the clinical course of these problems in a sibling or parent may help to reassure the family about spontaneous resolution and lack of long-term sequelae.",
"     </li>",
"     <li>",
"      Onset and clinical course: noticed at birth (external rotation hip contracture); when the child began walking (external tibial torsion [may worsen after age three] or [rarely] hip dislocation); after age three years (femoral retroversion); during adolescence (slipped capital femoral epiphysis); recent change (may indicate pathologic cause).",
"     </li>",
"     <li>",
"      Unilateral or bilateral? Symmetric or asymmetric? Unilateral or asymmetric out-toeing may be a red flag for cerebral palsy or slipped capital femoral epiphysis.",
"     </li>",
"     <li>",
"      Associated complaints: pain or limp (red flags for pathologic conditions); tripping or falling (may be an indication for referral if they persist beyond the normal age of resolution and are severe and disabling).",
"     </li>",
"     <li>",
"      Perceived difficulties caused by out-toeing (must be addressed during management). (See",
"      <a class=\"local\" href=\"#H141831169\">",
"       'Management'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141830466\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination serves to exclude pathologic causes of out-toeing, pinpoint rotational contributions, and identify associated angular problems (eg, bow legs). The examination should include observation of gait, focused examination of the lower extremity, and neurologic examination. In some cases, evaluation of the parental rotational profile also may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141830473\">",
"    <span class=\"h3\">",
"     Observation of gait",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the child is ambulatory, the child's gait should be observed as the child walks toward and away from the examiner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/2\">",
"     2",
"    </a>",
"    ]. The presence or absence of a limp should be noted. Additionally, the foot progression and patellar progression angles should be noted. These angles describe the alignment of the foot and patella, respectively, as they relate to the direction that the patient is moving.",
"    <strong>",
"    </strong>",
"    An external foot progression angle describes a foot that points toward the midline as the patient walks forward (",
"    <a class=\"graphic graphic_figure graphicRef75796 \" href=\"mobipreview.htm?17/13/17616\">",
"     figure 1",
"    </a>",
"    ). An external patellar progression angle describes a patella that points away from the midline as the patient walks forward. The common causes of out-toeing generally have reproducible gait patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      External tibial torsion &ndash; External foot progression angle, neutral or external patella progression angle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Femoral retroversion &ndash; External foot progression angle, external patella progression angle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      External rotation hip contracture &ndash; External foot progression angle, external patella progression angle",
"      <strong>",
"       .",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The child should also be observed while running [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6,18\">",
"     6,18",
"    </a>",
"    ]. Running may accentuate neurologic dysfunction and rotational variations. Unilateral limp while walking or running should raise suspicion of pathologic causes of out-toeing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141830480\">",
"    <span class=\"h3\">",
"     Focused examination of the lower extremities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the rotational alignment of the lower extremities is best done with the patient lying prone on the examination table [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/1\">",
"     1",
"    </a>",
"    ]. The parents should be encouraged to stand with the examiner next to the patient so that they can appreciate the findings as the examination is performed. The examination should progress through the three main sites for rotational variations: foot, tibia, and",
"    <span class=\"nowrap\">",
"     femur/hip.",
"    </span>",
"    This can be accomplished by making the following measurements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thigh-foot angle &ndash; The thigh-foot angle is measured with the knee flexed and the ankle dorsiflexed so that the plantar surface of the foot is parallel to the ceiling. Allow the foot to fall into a neutral position. A visual line is approximated along the long axis of the thigh and a second line along the long axis of the heel. The angle between these two lines is the thigh-foot angle (",
"      <a class=\"graphic graphic_figure graphicRef68556 \" href=\"mobipreview.htm?34/22/35169\">",
"       figure 4",
"      </a>",
"      ). If the line of the heel points toward the midline relative to the thigh, it suggests internal torsion of the tibia. If the line of the heel points away from the midline relative to the thigh, it suggests external torsion of the tibia.",
"      <br/>",
"      <br/>",
"      Normal values for the thigh-foot angle were determined in a study of 1000 limbs of 500 subjects (all white) ranging in age from &lt;1 to 70 years (",
"      <a class=\"graphic graphic_figure graphicRef67096 \" href=\"mobipreview.htm?19/1/19487\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/19\">",
"       19",
"      </a>",
"      ]. The average thigh-foot angle at birth is 5 degrees (external) and increases to 15 degrees (external) at maturity.",
"     </li>",
"     <li>",
"      Hip rotation &ndash; Hip rotation is measured with the knees flexed. Internal rotation is measured by rotating the leg away from the axis of the body (rotating the hip internally). External rotation is measured by rotating the leg towards the axis of the body (rotating the hip externally). &nbsp;",
"      <br/>",
"      <br/>",
"      Normal values for hip rotation were determined in a study of 1000 limbs of 500 subjects (all white) ranging in age from &lt;1 to 70 years (",
"      <a class=\"graphic graphic_figure graphicRef71765 \" href=\"mobipreview.htm?26/0/26627\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/19\">",
"       19",
"      </a>",
"      ]. The average amount of internal hip rotation during childhood is between 40 and 50 degrees. The average amount of external hip rotation during childhood is between 40 and 70 degrees.",
"      <br/>",
"      <br/>",
"      Patients with femoral retroversion will have increased external rotation (to almost 90 degrees) and very little internal rotation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/16\">",
"       16",
"      </a>",
"      ]. Conversely, patients with increased femoral anteversion may have as much as 90 degrees of internal rotation, allowing the legs to rotate flat against the exam table. Similarly, they will have a decreased amount of external rotation, often only to neutral.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other aspects of the lower-extremity examination that may be helpful in identifying associated conditions and excluding pathologic causes of out-toeing include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment for associated angular variations (knock-knees are associated with external tibial torsion) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/55/27511?source=see_link&amp;anchor=H4#H4\">",
"       \"Approach to the child with bow-legs\", section on 'Physiologic varus'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6199?source=see_link&amp;anchor=H4#H4\">",
"       \"Approach to the child with knock-knees\", section on 'Physiologic valgus'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Decreased hip internal rotation that is painful or associated with a limp (may indicate slipped capital femoral epiphysis; other clues include unilateral out-toeing and hip, thigh, or knee pain) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23209?source=see_link\">",
"       \"Slipped capital femoral epiphysis (SCFE)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141830487\">",
"    <span class=\"h3\">",
"     Parental rotational profiles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral retroversion and external tibial torsion tend to run in families. Assessment of the parents&rsquo; rotational profiles may help to predict how the child is likely to be affected as an adult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6\">",
"     6",
"    </a>",
"    ]. Such information may help to reassure the family about the lack of long-term functional problems. (See",
"    <a class=\"local\" href=\"#H141831169\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141830494\">",
"    <span class=\"h3\">",
"     Focused neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A focused neurologic examination is important to exclude cerebral palsy. The minimal neurologic examination should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upper- and lower-extremity reflexes",
"     </li>",
"     <li>",
"      Ankle clonus",
"     </li>",
"     <li>",
"      Measurement of popliteal angles to assess hamstring spasticity. The popliteal angle is measured by flexing the hip and the knee to 90 degrees and then extending the knee up to the point of mild resistance (",
"      <a class=\"graphic graphic_figure graphicRef79116 \" href=\"mobipreview.htm?32/27/33215\">",
"       figure 7",
"      </a>",
"      ). The popliteal angle is the angle between the tibia and the extension of the femur. Values &ge;50 to 55 degrees are considered abnormal in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asking the child to walk on his or her heels and toes and to hop on each leg. Heel walking demonstrates the ability to dorsiflex the ankle. Toe walking and hopping help to evaluate the child&rsquo;s overall motor coordination level (which varies with age).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141830502\">",
"    <span class=\"h2\">",
"     Radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs generally are not necessary in the assessment of out-toeing. External tibial torsion and femoral retroversion, the most common causes of out-toeing in infants and school-age children, are diagnosed clinically. Patients with unilateral out-toeing, pain, and limp should be evaluated for slipped capital femoral epiphysis with anteroposterior and frog leg (lateral) radiographs of the pelvis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23209?source=see_link&amp;anchor=H14#H14\">",
"     \"Slipped capital femoral epiphysis (SCFE)\", section on 'Plain radiographs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141831038\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with out-toeing can be followed in the primary care office. Indications for referral include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unilateral or asymmetric out-toeing associated with clinical findings suggestive of neurologic disorder (refer to a pediatric orthopedic surgeon, pediatric neurologist, or physical medicine and rehabilitation specialist).",
"     </li>",
"     <li>",
"      Children &ge;8 years with activity limiting or cosmetically unacceptable out-toeing due to external tibial torsion (may be candidates for derotational osteotomy; refer to an orthopedic surgeon with expertise in rotational problems).",
"     </li>",
"     <li>",
"      Children &ge;11 years with activity limiting or cosmetically unacceptable out-toeing due to femoral retroversion (may be candidates for derotational osteotomy; refer to an orthopedic surgeon with expertise in rotational problems).",
"     </li>",
"     <li>",
"      Patients with knee pain associated with a combination of external tibial torsion and increased femoral anteversion (&ldquo;miserable malalignment&rdquo;). This alignment combination can cause patellofemoral syndrome and may require tibial and femoral derotational osteotomies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=see_link\">",
"       \"Patellofemoral pain syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with hip, thigh, or knee pain who limp and have unilateral out-toeing and radiographs suggestive of slipped capital femoral epiphysis should be referred urgently to an orthopaedic surgeon for treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23209?source=see_link&amp;anchor=H18#H18\">",
"       \"Slipped capital femoral epiphysis (SCFE)\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141831169\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141831177\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the management of out-toeing is establishing a correct diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/3\">",
"     3",
"    </a>",
"    ]. The natural history of most rotational variations is spontaneous resolution as the child grows and develops. The most important (and usually only) intervention that is necessary for the majority of children with in-toeing or out-toeing is reassurance that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Out-toeing is a common developmental variation related to intrauterine positioning",
"     </li>",
"     <li>",
"      Although out-toeing is less likely to resolve than in-toeing and may be associated with an increased risk of hip or knee pain, treatment is only required if symptoms develop. &nbsp;",
"     </li>",
"     <li>",
"      Even if out-toeing does not completely resolve, long-term functional problems are rare (occurring in approximately 1 in 1000 children) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to address the concerns of the grandparents as well as the parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6\">",
"     6",
"    </a>",
"    ]. When the grandparents were raising their children, rotational variations were often considered to be a serious problem and were treated with interventions now known to be ineffective (eg, special shoes, orthotics). &nbsp;",
"   </p>",
"   <p>",
"    It may be helpful to ask the family to sit down in a public place and watch people walk by. They will notice considerable variation in the direction that people&rsquo;s feet point when they walk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141831309\">",
"    <span class=\"h2\">",
"     External rotation contracture of the hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of out-toeing due to hip external rotation contracture is that of spontaneous resolution. External rotation contracture of the hip is present in less than 5 percent of children by age 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/4\">",
"     4",
"    </a>",
"    ]. Treatment includes observation and parental reassurance that external rotation contracture of the hip is physiologic and resolves spontaneously. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141831317\">",
"    <span class=\"h2\">",
"     External tibial torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although external tibial torsion may increase with growth, it rarely becomes problematic before late childhood or adolescence. Symptoms and sequelae may include difficulty parallel skiing, patellofemoral instability, patellofemoral pain, knee arthritis, and osteochondritis dissecans of the knee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. When combined with increased femoral anteversion (&ldquo;miserable malalignment syndrome&rdquo;), patients may develop patellofemoral pain and instability. &nbsp;",
"   </p>",
"   <p>",
"    Most children with external tibial torsion can be managed with observation and parental reassurance that long term sequelae are rare. Bracing and splinting are ineffective. Derotational tibial osteotomy is the only effective treatment, but should be reserved for patients with knee pain, severe cosmetic and functional deformity, and an external thigh-foot angle greater than 40 degrees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141831325\">",
"    <span class=\"h2\">",
"     Femoral retroversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral retroversion is unlikely to resolve spontaneously. Bracing and twister cables are ineffective in correcting the version of the femur. Derotational osteotomy may be indicated in patients with hip pain, severe gait disturbance, or cosmetic deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141831379\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a large variation in lower-extremity rotational alignment in children. The most common causes of out-toeing in children are external rotation contracture of the hip, external tibial torsion, and femoral retroversion (",
"      <a class=\"graphic graphic_table graphicRef80335 \" href=\"mobipreview.htm?6/15/6397\">",
"       table 2",
"      </a>",
"      ). These rotational variations are related to intrauterine molding and often resolve spontaneously through normal growth and development. (See",
"      <a class=\"local\" href=\"#H141828373\">",
"       'Normal physiologic alignment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H141829701\">",
"       'Common causes of out-toeing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physiologic external rotation contracture of the hip is caused by intrauterine positioning and present in children from birth until they begin to walk. External rotation contracture of the hip is characterized by external foot and patella progression angles, increased external rotation, and decreased internal rotation. It usually resolves when children begin to walk. (See",
"      <a class=\"local\" href=\"#H141829708\">",
"       'External rotation contracture of the hip'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      External tibial torsion is external (lateral) rotation of the tibia in relation to the transcondylar axis of the femur. It may be associated with prematurity and prone positioning. It is characterized by an external foot progression angle and neutral or internal patella progression angle; and medial malleolus even with or anterior to the lateral malleolus. External tibial torsion usually does not correct spontaneously and may increase with growth. Although most patients with external tibial torsion remain asymptomatic, there may be an increased risk of patellofemoral pain or instability and knee arthritis. Symptomatic patients may require derotational osteotomy. (See",
"      <a class=\"local\" href=\"#H141829715\">",
"       'External tibial torsion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Femoral retroversion is a rare cause of out-toeing. It is characterized by a decreased angle of rotation of the femoral neck in relation to the transcondylar axis of the femur; gait with outward facing feet and knees; and increased hip external rotation and decreased internal rotation. Femoral retroversion does not improve spontaneously and may be associated with hip or knee arthritis, stress fracture, and slipped capital femoral epiphysis. (See",
"      <a class=\"local\" href=\"#H141829722\">",
"       'Femoral retroversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pathologic conditions that must be considered in the evaluation of a child with out-toeing include slipped capital femoral epiphysis (SCFE), Legg-Calv&eacute;-Perthes disease (idiopathic osteonecrosis of the hip), and neuromuscular disorders. Among these, SCFE is the most important to exclude. Anteroposterior and frog leg (lateral) radiographs of the pelvis should be obtained in children with unilateral out-toeing associated with hip, thigh, or knee pain and decreased internal rotation of the hip. Children with radiographs suggestive of SCFE should be urgently referred to an orthopedic surgeon. (See",
"      <a class=\"local\" href=\"#H141829729\">",
"       'Uncommon pathologic causes of out-toeing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H141830452\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23209?source=see_link\">",
"       \"Slipped capital femoral epiphysis (SCFE)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most children with rotational variations of the lower extremity can be followed in the primary care office. The most important aspect of management of rotational causes of out-toeing is parental reassurance that most &ldquo;deformities&rdquo; correct spontaneously and that, even in persistent cases, adverse long-term sequelae are rare. Nonoperative interventions (eg, shoe inserts, braces, twister cables, casting) are ineffective in the treatment of internal and external tibial torsion and increased femoral anteversion and femoral retroversion. We recommend against such interventions (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H141831169\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for referral for out-toeing include external tibial torsion and femoral retroversion associated with severe cosmetic or functional problems, hip pain, or knee pain; unilateral out-toeing associated with limp, hip pain, or knee pain; and out-toeing with concern for slipped capital femoral epiphysis. (See",
"      <a class=\"local\" href=\"#H141831038\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Schoenecker PL, Rich MM. The lower extremity. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1158.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/2\">",
"      LeDamany P. La torsion du tibia, normal, pathologique, experimentale. J Anat Physiol 1909; 45:598.",
"     </a>",
"    </li>",
"    <li>",
"     Staheli LT. Lower limb. In: Fundamentals of Pediatric Orthopedics, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/4\">",
"      Pitkow RB. External rotation contracture of the extended hip. A common phenomenon of infancy obscuring femoral neck anteversion and the most frequent cause of out-toeing gait in children. Clin Orthop Relat Res 1975; :139.",
"     </a>",
"    </li>",
"    <li>",
"     Johnston CE. Disorders of the leg. In: Tachdjian's Pediatric Orthopaedics, 4th, Herring JA (Ed), Saunders, Philadelphia 2008. p.973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/6\">",
"      Staheli LT. Rotational problems in children. Instr Course Lect 1994; 43:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/7\">",
"      Katz K, Krikler R, Wielunsky E, Merlob P. Effect of neonatal posture on later lower limb rotation and gait in premature infants. J Pediatr Orthop 1991; 11:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/8\">",
"      Winter WG Jr, Lafferty JF. The skiing sequelae of tibial torsion. Orthop Clin North Am 1976; 7:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/9\">",
"      Turner MS, Smillie IS. The effect of tibial torsion of the pathology of the knee. J Bone Joint Surg Br 1981; 63-B:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/10\">",
"      Scherl SA. Common lower extremity problems in children. Pediatr Rev 2004; 25:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/11\">",
"      Karol LA. Rotational deformities in the lower extremities. Curr Opin Pediatr 1997; 9:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/12\">",
"      T&ouml;nnis D, Heinecke A. Diminished femoral antetorsion syndrome: a cause of pain and osteoarthritis. J Pediatr Orthop 1991; 11:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/13\">",
"      Giladi M, Milgrom C, Stein M, et al. External rotation of the hip. A predictor of risk for stress fractures. Clin Orthop Relat Res 1987; :131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/14\">",
"      Pritchett JW, Perdue KD. Mechanical factors in slipped capital femoral epiphysis. J Pediatr Orthop 1988; 8:385.",
"     </a>",
"    </li>",
"    <li>",
"     Muscular Affectations of the Muscular System. In: Clinical Pediatric Orthopaedics: The Art of Diagnosis and Principles of Management, Tachdjians, MO (Eds), Appleton and Lange, Stamford 1997. p.381.",
"    </li>",
"    <li>",
"     Tachdjian MO. The knee and leg. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton and Lange, Stamford 1997. p.87.",
"    </li>",
"    <li>",
"     Tachdjian MO. Generalized affectations of the muscular skeletal system. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton and Lange, Stamford 1997. p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/18\">",
"      Bruce RW Jr. Torsional and angular deformities. Pediatr Clin North Am 1996; 43:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/19\">",
"      Staheli LT, Corbett M, Wyss C, King H. Lower-extremity rotational problems in children. Normal values to guide management. J Bone Joint Surg Am 1985; 67:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/20\">",
"      Katz K, Rosenthal A, Yosipovitch Z. Normal ranges of popliteal angle in children. J Pediatr Orthop 1992; 12:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30823/abstract/21\">",
"      Kuo L, Chung W, Bates E, Stephen J. The hamstring index. J Pediatr Orthop 1997; 17:78.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15691 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-118.195.65.248-57510F31CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30823=[""].join("\n");
var outline_f30_6_30823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H141831379\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141828000\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141828373\">",
"      NORMAL PHYSIOLOGIC ALIGNMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141829701\">",
"      COMMON CAUSES OF OUT-TOEING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141829708\">",
"      External rotation contracture of the hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141829715\">",
"      External tibial torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141829722\">",
"      Femoral retroversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141829729\">",
"      UNCOMMON PATHOLOGIC CAUSES OF OUT-TOEING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141830149\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141830452\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141830459\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141830466\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H141830473\">",
"      - Observation of gait",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H141830480\">",
"      - Focused examination of the lower extremities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H141830487\">",
"      - Parental rotational profiles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H141830494\">",
"      - Focused neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141830502\">",
"      Radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141831038\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141831169\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141831177\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141831309\">",
"      External rotation contracture of the hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141831317\">",
"      External tibial torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141831325\">",
"      Femoral retroversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141831379\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/15691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15691|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/13/17616\" title=\"figure 1\">",
"      In-toeing and out-toeing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/33/26129\" title=\"figure 2\">",
"      Lower extremity rotational alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/62/37858\" title=\"figure 3\">",
"      Intrauterine position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/22/35169\" title=\"figure 4\">",
"      Thigh foot angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/1/19487\" title=\"figure 5\">",
"      Physiologic progression of the thigh-foot angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/0/26627\" title=\"figure 6\">",
"      Normal hip rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/27/33215\" title=\"figure 7\">",
"      Measurement of popliteal angle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/15691|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/4/13387\" title=\"table 1\">",
"      Physiologic progression of lower-extremity rotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/15/6397\" title=\"table 2\">",
"      Common causes of out-toeing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/55/27511?source=related_link\">",
"      Approach to the child with bow-legs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42264?source=related_link\">",
"      Approach to the child with in-toeing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6199?source=related_link\">",
"      Approach to the child with knock-knees",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4104?source=related_link\">",
"      Diagnosis and classification of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43993?source=related_link\">",
"      Patellofemoral pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_6_30824="Statins and chronic kidney disease";
var content_f30_6_30824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Statins and chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30824/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30824/contributors\">",
"     Behdad Afzali, MRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30824/contributors\">",
"     David JA Goldsmith, MA, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30824/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30824/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/6/30824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal individuals demonstrate a decline in renal function over time. Above the age of 30, this amounts to an average decrease of 0.7 to 0.9",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in the glomerular filtration rate (GFR) per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/1\">",
"     1",
"    </a>",
"    ]. Once renal injury has occurred, independent of etiology, the decline in GFR can be accelerated by hypertension, proteinuria, and possibly by dyslipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of decline in GFR in established chronic kidney disease (CKD) can be decelerated with early intervention. Perhaps the most successful intervention is the reduction of elevated blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/5\">",
"     5",
"    </a>",
"    ], and there may be an added benefit to using angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers particularly in those with significant proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In animals, dyslipidemia is causally associated with glomerular injury, leading to the development of glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. However, this does not correlate with human studies in which lipid-rich conditions, such as familial hyperlipidemia, do not seem to lead to clinically-relevant renal injury. Perhaps this is due to earlier development of significant cardiovascular disease or targeted interventional therapy. On the other hand, once CKD has been established, small series have demonstrated an association between progression of renal disease and hyperlipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary analyses of data on subsets of patients with decreased kidney function recruited into several trials of hypertensive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dyslipidemic cohorts have helped to clarify some of these issues. However, in interpreting these post-hoc analyses, it is important to exercise considerable caution as renal dysfunction was not the primary objective of the studies and significant inaccuracies may accrue as a result of subanalysis, with increased risk of type I errors. In addition, the evaluation of renal function in these post-hoc analyses typically is done using formulaic manipulation of plasma creatinine levels, with all of the obvious short-comings of this methodology.",
"   </p>",
"   <p>",
"    The evidence linking dyslipidemia management with statins to the decline in renal function will be presented in this topic review. Additional reasons for the use of statins in those with renal disease, including an overview of its possible benefits in decreasing the risk of adverse cardiovascular outcomes, will also be presented briefly. Overviews of the use of statins in patients without renal failure are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to discussing the effects of statins on clinical outcomes in patients with renal disease, such as progressive renal dysfunction and cardiovascular disease, a review of some of the effects of statins that may underlie these benefits will be discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Vascular stiffness and endothelial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular stiffness is one of the important predictors of mortality in hemodialysis and renal transplant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The reasons for increased stiffness in renal failure patients are diverse and include both functional and structural alterations, some of which are also seen with older age and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Beneficial effects of statins on vessel stiffening and endothelial function in renal failure have been described. As examples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-six patients who had undergone renal transplantation were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      40 mg daily or placebo and followed for three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/14\">",
"       14",
"      </a>",
"      ]. Baseline and 6, 12, and 36 monthly endothelium-dependent flow-mediated vasodilatation (FMD) and other measures of the brachial artery were measured. A significant decrease in total and low-density cholesterol was observed after 6, 12, and 36 months in patients treated with fluvastatin but not in the placebo group. In addition, there was a concomitant increase in FMD with fluvastatin after 12 months; this improvement was sustained at 13.4 percent after 36 months. Other differences between the two groups were not observed.",
"     </li>",
"     <li>",
"      In another study that examined large artery stiffness in type II diabetics on hemodialysis, 22 patients with normal serum lipids were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      20 mg daily or placebo for a total of six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/15\">",
"       15",
"      </a>",
"      ]. Serum lipid levels, serum levels of CRP and measures of arterial stiffness (arterial PWV, and ankle brachial indexes [ABI]) were determined at baseline, three, and six months after taking the medication. After six months, the placebo-treated arm demonstrated a significant increase in the PWV and the serum oxidized low-density lipoprotein cholesterol. In contrast, the active treatment arm had a significantly reduced PWV, oxidized LDL-C serum levels, and CRP (from 0.97 to 0.26",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      compared with those in the placebo group.",
"     </li>",
"     <li>",
"      With respect to endothelial function, 60 normotensive patients with type 2 diabetes, microalbuminuria, and dyslipidemia received either cerivastatin or placebo for six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/16\">",
"       16",
"      </a>",
"      ]. Cerivastatin significantly reduced total cholesterol, LDL cholesterol and triglycerides levels and urinary albumin excretion, suggesting that modifications of endothelial function by statins may be important in modulating glomerular proteinuria. There are other short-term statin-administration trials that purport to show reductions in urinary albumin excretion, but considerable caution should be exercised here, as this is not a completely reliable surrogate end-point for important renal outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Inflammation and end-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is growing evidence for an anti-inflammatory role for statins in patients without renal failure. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence for a similar effect with statins in patients with kidney failure is emerging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/18\">",
"     18",
"    </a>",
"    ]. One randomized study, for example, evaluated the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (20 mg daily) versus placebo on markers of inflammation in 62 hemodialysis patients with serum cholesterol levels greater than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/19\">",
"     19",
"    </a>",
"    ]. Cholesterol, albumin, and high-sensitivity C-reactive protein (hs-CRP) were measured at baseline and again at eight weeks. Unlike the control group in which there was no change in these markers, active therapy significantly reduced total cholesterol levels (232 to 165",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and hs-CRP levels (0.23 to 0.12",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    and increased serum albumin levels (3.4 to 3.6",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"   </p>",
"   <p>",
"    A beneficial effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    on inflammatory markers (CRP, IL-6) was also reported in a randomized study of 55 patients with chronic kidney disease not on dialysis (mean creatinine clearance 45",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results are suggestive that, in addition to its lipid-lowering effects,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    has an antiinflammatory effect in patients with CKD. The mechanism for the antiinflammatory effect of statins is unclear, but may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFECT OF DYSLIPIDEMIA ON KIDNEY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, normal individuals demonstrate a decline in kidney function over time. Once renal injury has occurred, the yearly decline in GFR may be accelerated and perpetuated by dyslipidemia. However, the supportive data were largely derived from post-hoc analyses of several large trials, which may be limited by unmeasured confounders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Helsinki Heart Study recruited 2702 dyslipidemic (non-HDL cholesterol &gt;5.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      men with \"normal renal function\" (defined as serum creatinine concentration &lt;1.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [115",
"      <span class=\"nowrap\">",
"       micromol/L]),",
"      </span>",
"      although 30 men were included with levels between 1.3 and 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (116 and 135",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/22\">",
"       22",
"      </a>",
"      ]. The patients were randomly assigned to 1200 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      daily plus dietary advice or placebo and dietary advice. At five years of follow-up, mean serum creatinine levels had increased an average of 3 percent in both groups (an increase of about 5 to 6",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      A low- to high-density lipoprotein ratio of greater than 4.4 was associated with a 20 percent faster decline than a ratio of less than 3.2, a result that remained significant despite multiple regression analyses.",
"     </li>",
"     <li>",
"      The Physicians' Health Study recruited and monitored 4483 healthy men between 1982 and 1996 with predefined primary endpoints of an elevated serum creatinine level (defined as &gt;1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [133",
"      <span class=\"nowrap\">",
"       micromol/L]),",
"      </span>",
"      and reduced estimated creatinine clearance, defined as &lt;55",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/23\">",
"       23",
"      </a>",
"      ]. Cholesterol parameters included total cholesterol (&lt;200, 200 to 239, and &gt;240",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      HDL (&lt;40",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      total non-HDL cholesterol, and the ratio of total cholesterol to HDL. After 14 years, 134 men (3.0 percent) had elevated serum creatinine levels and 244 (5.4 percent) had reduced creatinine clearance. Dyslipidemia was significantly associated with an increased risk of developing renal dysfunction in men with an initial creatinine concentration of less than 133",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      (relative risk 1.68 for total cholesterol &gt;240",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      2.12 for HDL &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      2.22 for the highest quartile of total",
"      <span class=\"nowrap\">",
"       cholesterol/HDL",
"      </span>",
"      ratio [&gt;6.8] and 2.03 for the highest quartile of non-HDL cholesterol [&gt;196.1",
"      <span class=\"nowrap\">",
"       mg/dL])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A substudy of the Lipid Research Clinics Coronary Primary Prevention Trial examined the effect of cholesterol reduction with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      on kidney function among 3603 middle aged men randomly assigned to treatment versus control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/24\">",
"       24",
"      </a>",
"      ]. After seven years, there was a significant decrease in total and LDL cholesterol in the treatment group, and no difference in the control group. The mean baseline estimated GFR was 86",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 in both the treatment and control groups, with a similar increase in GFR in both groups (by 4",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these trials and others have examined the interaction between dyslipidemia and decreases in renal function, some of the effects reported have been fairly modest. Such post-hoc analyses are also limited by unmeasured confounders that are closely correlated to dyslipidemia. As an example, in a post-hoc analysis of the Atherosclerosis Risk in Communities (ARIC) study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/25\">",
"     25",
"    </a>",
"    ], the observed temporal association between hypertriglyceridemia and low HDL-cholesterol and an increase in serum creatinine concentration was considerably attenuated after adjustment for measures of insulin resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     STATINS AND KIDNEY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the effect of statin therapy on renal outcomes in patients with chronic kidney disease (CKD). The end points have included protein excretion and progression of CKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156847860\">",
"    <span class=\"h2\">",
"     Effect on protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large body of evidence supports the correlation among blood pressure control, proteinuria reduction, and improved renal outcomes in patients with proteinuric CKD. Urinary protein excretion varies directly with the intraglomerular pressure, and lowering intraglomerular pressure with ACE inhibitors and angiotensin II receptor blockers is at least a partial explanation for their benefit in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proteinuria may also directly contribute to disease progression. This observation suggests that lowering proteinuria alone, independent of any reduction in intraglomerular pressure or systemic blood pressure, may diminish renal damage. In addition, proteinuria is an independent risk factor for cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H5#H5\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analyses of the first postmarketing year reported to the Food and Drug Administration of the United States showed different rates of increased protein excretion with various statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/26\">",
"     26",
"    </a>",
"    ]. Higher rates were observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    . However, clinical studies that specifically evaluated the effect of statin therapy on protein excretion yielded conflicting results, with some demonstrating a reduction in proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/27-29\">",
"     27-29",
"    </a>",
"    ] and others showing no effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two meta-analyses using similar criteria for trial inclusion synthesized the results from small randomized trials (ranging from 18 to 82 patients) that, as a secondary outcome, evaluated the effect of statin use on albuminuria or proteinuria; trial inclusion into these two meta-analyses was similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/29,32\">",
"     29,32",
"    </a>",
"    ]. The first meta-analysis of 382 patients reported a significant 48 percent reduction in albumin excretion with statin therapy in patients with microalbuminuria (30 to 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and those with macroalbuminuria (more than 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/29\">",
"     29",
"    </a>",
"    ]. The second meta-analysis of 311 patients reported a significant mean absolute reduction in albumin excretion of 730",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    a result that was probably driven by findings in patients with macroalbuminuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/32\">",
"     32",
"    </a>",
"    ]. In only one of the trials included in these meta-analyses was the use of angiotensin blockers uniform, while at least four of the included trials employed no angiotensin blockers.",
"   </p>",
"   <p>",
"    Two subsequent large-scale randomized trials found no effect of statins on albumin excretion in patients who received optimal therapy for slowing CKD progression with angiotensin blockers and good blood pressure control:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the PREVEND-IT trial, 864 patients with a urinary albumin excretion between 15 and 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and a mean blood pressure of",
"      <span class=\"nowrap\">",
"       130/76",
"      </span>",
"      mmHg at baseline were randomly assigned in a 2x2 factorial design to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      or placebo and to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/30/16872?source=see_link\">",
"       fosinopril",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/30\">",
"       30",
"      </a>",
"      ]. Pravastatin had no effect on albumin excretion at 4 years of follow-up, regardless of whether patients were or were not also treated with fosinopril.",
"     </li>",
"     <li>",
"      The ESPLANADE trial evaluated the effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      compared with placebo on the six-month change in protein excretion among 186 patients with persistent proteinuria (at least 500",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      despite prior treatment with dual angiotensin blockade and well controlled blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/31\">",
"       31",
"      </a>",
"      ]. No reduction in proteinuria was observed with fluvastatin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156847721\">",
"    <span class=\"h2\">",
"     Effect on CKD progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a dearth of studies using cholesterol lowering as the intervention and renal function as the primary outcome in patients with and without renal dysfunction. As a result, the relationship between these factors has to be evaluated by examining post-hoc analyses of subsets of patients recruited into cardiovascular clinical trials. Although most of these studies attempted to exclude patients with CKD based upon serum creatinine concentration alone, many subjects were unintentionally included with reduced estimated glomerular filtration rates.",
"   </p>",
"   <p>",
"    There are conflicting data concerning the effect of statins on progression of CKD. Some studies suggest that statins slow the rate of decline in renal function in patients with mild to moderate renal dysfunction, while others have found that statins are no different than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/33-45\">",
"     33-45",
"    </a>",
"    ]. The possible mechanisms by which hyperlipidemia might promote disease progression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H11#H11\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Hyperlipidemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the trials that evaluated the effect of statin therapy on CKD progression were subset analyses of trials designed to evaluate the efficacy of statin therapy on cardiovascular disease. The following are examples of studies that have reported a positive effect of statins on the rate of progression of chronic kidney disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CARE (Cholesterol And Recurrent Events) trial recruited 4159 hyperlipidemic subjects with a history of myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/33\">",
"       33",
"      </a>",
"      ]. Patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      or placebo and their cardiovascular morbidity and mortality was followed for five years. A post-hoc subgroup analysis on 690 patients with estimated GFRs of less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73m2 body surface area at baseline showed that the loss of GFR over time in the pravastatin group was not significantly different from that in the placebo group (0.1",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73",
"      <span class=\"nowrap\">",
"       m2/year",
"      </span>",
"      slower).",
"      <br/>",
"      <br/>",
"      However, benefit was observed in those with baseline proteinuria and in those with lower baseline GFRs (rate of change of GFR in the pravastatin group was 0.6",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73",
"      <span class=\"nowrap\">",
"       m2/year",
"      </span>",
"      slower than placebo in those with baseline GFR &lt;50",
"      <span class=\"nowrap\">",
"       mL/min;",
"      </span>",
"      and 2.5",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73",
"      <span class=\"nowrap\">",
"       m2/year",
"      </span>",
"      slower in those with a GFR &lt;40",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 at baseline) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/34\">",
"       34",
"      </a>",
"      ]. The possible benefit was associated with improvement in markers of inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subgroup analysis of the Treating to New Targets (TNT) trial compared the effect of 80 versus 10 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      on progression of estimated GFR (eGFR) among 10,001 patients with coronary artery disease (baseline eGFR of 65",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. At follow-up at five years, the mean eGFR increased in both groups, with a greater increase observed in the 80 mg group (increase of 5.2 versus 3.5",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"     </li>",
"     <li>",
"      The Prospective",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      Pooling project combined data from three trials comparing pravastatin to placebo with approximately five years of follow-up: CARE described above, WOSCOPS, and LIPID [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/40\">",
"       40",
"      </a>",
"      ]. There were 3400 individuals with moderate CKD (MDRD formula GFR of 30 to 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2). ACE inhibitor use and blood pressure at baseline and follow-up were similar in the pravastatin and placebo groups. The overall rate of decline of GFR was 0.7",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year; the adjusted rate of progression in the pravastatin group was reduced by 34 percent (absolute difference of 0.2",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year). There was no significant effect of pravastatin in patients with better kidney function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there are other trials that have found that statins do",
"    <strong>",
"     not",
"    </strong>",
"    decrease the rate of progression of renal dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A secondary analysis of the PREVEND-IT trial, which included 864 patients with albuminuria and relatively preserved GFR, found no difference in the change in GFR between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      and placebo at four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Post-hoc analysis of the ALLHAT-LLT study found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      and placebo had similar effects on the rates of end-stage renal disease (ESRD) and decreases in GFR over a six-year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2009 systematic review and meta-analysis found no significant improvement in creatine clearance as noted in 11 studies of 548 patients (mean difference 1.58",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      95% CI -2.32-5.28) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Study of Heart and Renal Protection (SHARP) trial,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"        simvastatin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"        ezetimibe",
"       </a>",
"      </span>",
"      therapy compared with placebo did not decrease the risk of progression to ESRD in patients who were not on dialysis at baseline (33.9 versus 34.6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link&amp;anchor=H8853471#H8853471\">",
"       \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\", section on 'SHARP trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A 2012 meta-analysis that included two studies published in 2008 and 2010 found no reduced risk for ESRD, although it could be argued that the 95% confidence interval of the relative risk (RR 0.98, 95% CI 0.62-1.56) includes a clinically important reduction or increase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/45\">",
"       45",
"      </a>",
"      ]. The results of this meta-analysis are thus not conclusive.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these conflicting results, statin therapy cannot be recommended solely for renal protection. Effects on proteinuria, if any, may be dose or even drug dependent and are likely to be limited to patients who are not receiving optimal therapy to slow CKD progression. Effects of statins on GFR may be modest or insignificant.",
"   </p>",
"   <p>",
"    However, as discussed in the next section, patients with CKD not yet on dialysis are candidates for statin therapy due to cardiovascular protection alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     STATINS AND CARDIOVASCULAR OUTCOMES IN CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild CKD and microalbuminuria are associated with an increase in susceptibility to cardiovascular disease and are now considered to be coronary artery disease equivalents. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1317041\">",
"    <span class=\"h2\">",
"     Patients on dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized trials, including 4D, AURORA, and SHARP have examined the effect of statin therapy on cardiovascular outcomes in patients with end-stage renal disease requiring dialysis. Findings from these trials, as well as recommendations pertaining to statin therapy in dialysis patients, is discussed separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/554?source=see_link&amp;anchor=H5#H5\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\", section on 'Trials of statin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1317048\">",
"    <span class=\"h2\">",
"     Patients not on dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SHARP trial examined the effect of statin therapy (given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    ) in patients with CKD not on dialysis. The effect of statin therapy on cardiovascular endpoints in CKD patients has also been evaluated in post-hoc analyses of randomized trials that inadvertently enrolled patients with CKD. Detailed discussions, as well as recommendations concerning statins and cardiovascular disease in patients with CKD not on dialysis, are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link&amp;anchor=H6#H6\">",
"     \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\", section on 'Cholesterol lowering with a statin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     STATINS AND SEPSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies in patients without CKD suggested that statin therapy may decrease the rates of severe sepsis and mortality from sepsis. Among 1041 dialysis patients, a prospective cohort study also found a reduction in the risk of sepsis with statin therapy (incidence rate ratio 0.41, CI 0.25-0.68) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/50\">",
"     50",
"    </a>",
"    ]; the apparent protective effect was even larger with additional adjustment for comorbidities or with propensity matching. However, it needs to be remembered that this report is a secondary analysis of the 4-D study, and the original study was neither designed nor powered for sepsis end-points. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=see_link\">",
"     \"Statins: Possible noncardiovascular benefits\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS OF STATINS IN CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to adverse effects, studies in CKD, dialysis patients, and renal transplant recipients suggest good side effect profiles with statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/33,51-53\">",
"     33,51-53",
"    </a>",
"    ]. The safety of a statin in patients with CKD was perhaps best evaluated in the first United Kingdom Heart and Renal Protection (UK-HARP-I) study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30824/abstract/53\">",
"     53",
"    </a>",
"    ]. In this pilot safety trial, 448 patients with CKD (242 predialysis patients with a serum creatinine concentration &ge;1.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&ge;150",
"    <span class=\"nowrap\">",
"     micromol/L],",
"    </span>",
"    73 dialysis patients, and 133 with a renal allograft) were randomly assigned in a 2x2 design to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo and modified-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo. A similar risk for abnormal liver function tests or elevated creatine kinase levels was reported for simvastatin and placebo.",
"   </p>",
"   <p>",
"    However, accurate estimates of the risk of adverse events (especially myopathy) are not available in published reports of patients with ESRD or moderate to severe CKD, since the existing clinical trials with statins in these cohorts have been quite small. Nevertheless, results from the 4-D trial in dialysis patients, the ALERT trial in renal transplant recipients, and others suggest that the general incidence of statin-related side effects is low in this patient population. As with other drugs, close attention must be paid to drug interactions and proper dosing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=see_link\">",
"     \"Lipid abnormalities after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is indirect evidence of beneficial effects of statins on vessel stiffening and endothelial function in patients with chronic kidney disease (CKD). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiologic effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once renal injury has occurred, the yearly decline in glomerular filtration rate (GFR) may be accelerated and perpetuated by dyslipidemia. However, this effect has been derived from post-hoc analyses, which are limited by unmeasured confounders that are closely correlated to dyslipidemia. If real, this effect is fairly modest. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Effect of dyslipidemia on kidney function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two meta-analyses of small randomized trials found that statin therapy significantly reduced albuminuria. However, patients in the trials that were included in these meta-analyses were not uniformly taking angiotensin blockade. In contrast, two large-scale randomized trials found no effect of statins on albumin excretion in patients who received optimal therapy for slowing CKD progression with angiotensin blockers and good blood pressure control. (See",
"      <a class=\"local\" href=\"#H156847860\">",
"       'Effect on protein excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are conflicting data concerning the effect of statins on progression of CKD. Some studies suggest that statins slow the rate of decline in renal function in patients with mild to moderate renal dysfunction, while others have found that statins are no different than placebo. All of the trials that evaluated the effect of statin therapy on CKD progression were subset analyses of trials designed to evaluate the efficacy of statin therapy on cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H156847721\">",
"       'Effect on CKD progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thus, statin therapy cannot be recommended solely for renal protection. Effects on proteinuria, if any, are likely to be limited to patients who are not receiving optimal therapy to slow CKD progression. Effects of statins on GFR may be modest or insignificant.",
"     </li>",
"     <li>",
"      However, patients with CKD may be candidates for statin therapy for cardiovascular protection. The effect of statin therapy on cardiovascular endpoints and recommendations concerning the use of statins in dialysis patients and CKD patients not on dialysis are presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/554?source=see_link&amp;anchor=H4#H4\">",
"       \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\", section on 'Lipid modification'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=see_link&amp;anchor=H6#H6\">",
"       \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\", section on 'Cholesterol lowering with a statin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With respect to adverse effects, good side effect profiles with statins have been reported patients with CKD, dialysis patients, renal transplant recipients. However, accurate estimates of the risk of adverse events (especially myopathy) are not available in patients with ESRD or moderate to severe chronic renal insufficiency, since the existing clinical trials with statins in these patients have been quite small. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Adverse effects of statins in CKD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/1\">",
"      Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/2\">",
"      Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/3\">",
"      Parving HH, Smidt UM, Friisberg B, et al. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 1981; 20:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/4\">",
"      Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular function in diabetic nephropathy. A prospective study. Am J Med 1983; 74:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/5\">",
"      Taal MW, Brenner BM. Evolving strategies for renoprotection: non-diabetic chronic renal disease. Curr Opin Nephrol Hypertens 2001; 10:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/6\">",
"      Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol 1988; 8:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/7\">",
"      Lambert G, Sakai N, Vaisman BL, et al. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. J Biol Chem 2001; 276:15090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/8\">",
"      M&uuml;hlfeld AS, Spencer MW, Hudkins KL, et al. Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice. Kidney Int 2004; 66:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/9\">",
"      Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/10\">",
"      Konstadinidou I, Boletis JN, Perrea D, et al. Beneficial effects of fluvastatin on progressive renal allograft dysfunction. Transplant Proc 2003; 35:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/11\">",
"      Barenbrock M, Kosch M, J&ouml;ster E, et al. Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation. J Hypertens 2002; 20:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/12\">",
"      Goldsmith D, MacGinley R, Smith A, Covic A. How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure? Nephrol Dial Transplant 2002; 17:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/13\">",
"      Blacher J, Safar ME, Pannier B, et al. Prognostic significance of arterial stiffness measurements in end-stage renal disease patients. Curr Opin Nephrol Hypertens 2002; 11:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/14\">",
"      Kosch M, Barenbrock M, Suwelack B, et al. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am J Kidney Dis 2003; 41:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/15\">",
"      Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/16\">",
"      Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 2001; 21:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/17\">",
"      Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007; 49:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/18\">",
"      Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005; 45:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/19\">",
"      Chang JW, Yang WS, Min WK, et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/20\">",
"      Panichi V, Paoletti S, Mantuano E, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006; 21:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/21\">",
"      McCarty MF. Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. Med Hypotheses 2003; 60:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/22\">",
"      M&auml;ntt&auml;ri M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995; 26:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/23\">",
"      Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/24\">",
"      Kshirsagar AV, Shoham DA, Bang H, et al. The effect of cholesterol reduction with cholestyramine on renal function. Am J Kidney Dis 2005; 46:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/25\">",
"      Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/26\">",
"      Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111:3051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/27\">",
"      Ozsoy RC, Koopman MG, Kastelein JJ, Arisz L. The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis. Clin Nephrol 2005; 63:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/28\">",
"      Lee TM, Lin MS, Tsai CH, Chang NC. Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int 2005; 68:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/29\">",
"      Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/30\">",
"      Atthobari J, Brantsma AH, Gansevoort RT, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006; 21:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/31\">",
"      Ruggenenti P, Perna A, Tonelli M, et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol 2010; 5:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/32\">",
"      Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/33\">",
"      Tonelli M, Moy&eacute; L, Sacks FM, et al. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/34\">",
"      Tonelli M, Moy&eacute; L, Sacks FM, et al. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/35\">",
"      Tonelli M, Sacks F, Pfeffer M, et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/36\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/37\">",
"      Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/38\">",
"      Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/39\">",
"      Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/40\">",
"      Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/41\">",
"      Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/42\">",
"      Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006; 17:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/43\">",
"      Ozsoy RC, van der Steeg WA, Kastelein JJ, et al. Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. Nephrol Dial Transplant 2007; 22:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/44\">",
"      Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2008; 52:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/45\">",
"      Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012; 156:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/46\">",
"      Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007; 2:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/47\">",
"      Campese VM, Park J. HMG-CoA reductase inhibitors and renal function. Clin J Am Soc Nephrol 2007; 2:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/48\">",
"      Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; :CD007784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/49\">",
"      Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/50\">",
"      Gupta R, Plantinga LC, Fink NE, et al. Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA 2007; 297:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/51\">",
"      Harris KP, Wheeler DC, Chong CC, Atorvastatin in CAPD Study Investigators. Continuous ambulatory peritoneal dialysis. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 2002; 61:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/52\">",
"      Holdaas H, Fellstr&ouml;m B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30824/abstract/53\">",
"      Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45:473.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7192 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30824=[""].join("\n");
var outline_f30_6_30824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Vascular stiffness and endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Inflammation and end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFECT OF DYSLIPIDEMIA ON KIDNEY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      STATINS AND KIDNEY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H156847860\">",
"      Effect on protein excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H156847721\">",
"      Effect on CKD progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      STATINS AND CARDIOVASCULAR OUTCOMES IN CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1317041\">",
"      Patients on dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1317048\">",
"      Patients not on dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      STATINS AND SEPSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADVERSE EFFECTS OF STATINS IN CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/54/29546?source=related_link\">",
"      Lipid abnormalities after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6248?source=related_link\">",
"      Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/34/554?source=related_link\">",
"      Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_6_30825="Clinical features and diagnosis of chronic fatigue syndrome";
var content_f30_6_30825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of chronic fatigue syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30825/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30825/contributors\">",
"     Stephen J Gluckman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30825/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30825/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30825/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/6/30825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic fatigue syndrome (CFS) has received considerable attention but remains a complicated and controversial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/1\">",
"     1",
"    </a>",
"    ]. Much of this is due to the lack of objective findings. Nonetheless, patients with CFS have real symptoms and are not malingerers. The prevalence of this syndrome is unclear in part due to difficulties in proving the diagnosis. In one study of 1000 consecutive patients in a primary care clinic, for example, 8.5 percent had debilitating fatigue of at least six months duration without apparent cause; however, only 15 percent of these patients satisfied the clinical definition for CFS listed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of chronic fatigue syndrome are reviewed here. The general approach to a patient with fatigue and the treatment of CFS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23111?source=see_link\">",
"     \"Approach to the adult patient with fatigue\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4440?source=see_link\">",
"     \"Treatment of chronic fatigue syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important things a clinician can do when discussing chronic fatigue syndrome (CFS) with a patient is to review the history of this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. It is critical that the patient realizes that this is not a new disease, and reviewing the history will help to reassure the patient that the clinician is knowledgeable about CFS. The following is a brief historical review of the names applied to disorders that were remarkably similar to CFS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1750 &mdash; Febricula or little fever",
"     </li>",
"     <li>",
"      1871 &mdash; DaCosta's syndrome (effort syndrome, soldier's heart)",
"     </li>",
"     <li>",
"      1889 &mdash; Neurasthenia. In the 1880s, the neurologist George Beard named and promoted the term neurasthenia. Sir William Osler, writing in his Principles and Practice of Medicine in 1895, described neurasthenia with \"in all forms there is a striking lack of accordance between the symptoms of which the patients complains and the objective changes discoverable by the physician.\"",
"     </li>",
"     <li>",
"      1934 &mdash; An outbreak of myalgic encephalitis at Los Angeles General Hospital represented the \"epidemic\" form of this disease. Other such outbreaks have been called Iceland disease, Akureyri disease, and Royal Free disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific etiologies have also been ascribed to the CFS. The proposed diagnosis was chronic brucellosis from the 1930s to the 1950s and hypoglycemia from the 1950s to the 1970s. Other hypotheses have included chronic Epstein-Barr virus (EBV) infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], purported chronic Lyme disease, total allergy syndrome, multiple chemical sensitivity syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/8\">",
"     8",
"    </a>",
"    ], chronic candidiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/9\">",
"     9",
"    </a>",
"    ], and xenotropic murine leukemia virus-related virus (XMRV) and related retroviruses, such as murine leukemia virus (MLV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. None of these etiologic agents have been scientifically linked to the CFS.",
"   </p>",
"   <p>",
"    Other terms that have been used for CFS to reflect postulated etiologies include \"myalgic encephalomyelitis\" (in the United Kingdom) and \"chronic fatigue and immune dysfunction syndrome&rdquo; (CFIDS, in the United States) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the name CFS has the distinct advantage of not ascribing this disease to an incorrect cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1988, the United States Centers for Disease Control and Prevention (CDC) published a \"working case definition\" of chronic fatigue syndrome (CFS) containing 2 major criteria, 11 minor symptom criteria, and 3 physical examination criteria (",
"    <a class=\"graphic graphic_table graphicRef50332 \" href=\"mobipreview.htm?10/0/10252\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/13\">",
"     13",
"    </a>",
"    ]. Using these standards, a case of CFS was diagnosed if the patient's signs and symptoms fulfilled major criteria and either eight symptom criteria or six symptom and two physical criteria. However, field testing of this definition has found it lacking in several regards. A number of the elements are vague and redundant, and so many symptoms are required for diagnosis that there is a bias toward selection of patients with somatization disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 1992, the National Institute of Allergy and Infectious Diseases published suggested modifications to these criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/14\">",
"     14",
"    </a>",
"    ]. These modifications primarily excluded patients with psychoses and substance abuse but included fibromyalgia, somatoform disorders, and generalized",
"    <span class=\"nowrap\">",
"     anxiety/panic",
"    </span>",
"    disorder. These modifications recognized the considerable overlap between CFS and fibromyalgia; the majority of patients with CFS meet trigger point criteria for fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/15\">",
"     15",
"    </a>",
"    ]. Similarly, approximately 70 percent of patients with fibromyalgia meet the criteria for CFS (",
"    <a class=\"graphic graphic_table graphicRef56019 \" href=\"mobipreview.htm?15/57/16283\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further revision of the definition was made by the CDC and an international study group in 1994 (",
"    <a class=\"graphic graphic_table graphicRef55495 \" href=\"mobipreview.htm?34/8/34955\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients must have clinically evaluated, unexplained, persistent or relapsing fatigue plus four or more specifically defined associated symptoms; the requirement for any physical finding was removed.",
"   </p>",
"   <p>",
"    Requiring fatigue to be \"unexplained\" despite clinical evaluation should exclude most patients with well recognized diseases. However, the presence of such disorders may escape detection despite intensive evaluation. One possible example is a seronegative form of Sj&ouml;gren's syndrome (SS), which some claim to occur in some patients with CFS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. As an example, one small study compared the incidence of oral and ocular dryness, tear production, and lymphocytic infiltration of minor salivary glands among 25 patients with CFS and 18 healthy individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/21\">",
"     21",
"    </a>",
"    ]. Complaints of dryness were noted in 55 percent of those with CFS, but in none of the control group.",
"   </p>",
"   <p>",
"    An important aspect of the CDC analysis of CFS is the recognition that many people can have unexplained chronic fatigue and not fit the case criteria for CFS. Such individuals are defined as having idiopathic chronic fatigue. Idiopathic chronic fatigue may represent a different end of the spectrum of a continuum of illness that includes CFS. These diagnostic criteria are now under study to determine their validity.",
"   </p>",
"   <p>",
"    These clinical case definitions are standard epidemiologic tools that are employed when there is no diagnostic test for a specific disorder. They are \"intentionally restrictive, to maximize the chances that research studies will detect significant associations if such associations truly exist\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/13\">",
"     13",
"    </a>",
"    ]. Though a clinical case definition is a well established instrument, its strict application may not always be appropriate in the evaluation of a specific patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic fatigue is an extremely common complaint. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23111?source=see_link\">",
"     \"Approach to the adult patient with fatigue\"",
"    </a>",
"    .) Several studies have examined the incidence of chronic fatigue in both developed and developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 1159 patients in a primary care clinic in the United States found that 276 (24 percent) complained of fatigue for more than one month [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of approximately 2400 patients in an English primary care practice found that 214 (11 percent) had chronic fatigue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A population based survey of 2494 women in India found that 301 (12 percent) complained of fatigue for at least six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The chronic fatigue syndrome (CFS) represents a very small subset of those who complain of chronic fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. A random digit-dialing survey in Wichita, Kansas estimated the point prevalence of CFS to be 235 per 100,000; a one year telephone survey follow-up among those not fatigued or fatigued for &lt;6 months found the incidence of CFS to be 180 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/23\">",
"     23",
"    </a>",
"    ]. Similar findings were noted in a prospective cohort study of over 4000 patients in a health maintenance organization, the estimated crude point prevalence of CFS ranged from 75 to 267 cases per 100,000 persons; the point prevalence of chronic fatigue not meeting the syndromic definition was strikingly higher, ranging from 1775 to 6321 cases per 100,000 persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, even among patients with fatigue of at least six months duration, the prevalence of CFS is well under 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CFS is associated with the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is primarily a disorder of young to middle aged adults, but cases in children have been recognized. It may also occur in the elderly, although coexisting medical conditions usually preclude its consideration in this population.",
"     </li>",
"     <li>",
"      Most series report that CFS is about twice as common in women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Few cases have been reported in minorities or among lower socioeconomic groups. However, the incidence in these groups may be underestimated due to their lack of equivalent access to health care institutions in which CFS is studied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cases of CFS usually arise in a sporadic manner, although closely related (if not identical) illnesses have occurred in outbreaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/27-32\">",
"     27-32",
"    </a>",
"    ]. Other names for these types of outbreaks include epidemic neuromyasthenia and myalgic encephalomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. However, careful investigations of a putative \"cluster\" of CFS cases failed to reveal that there was a true epidemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROPOSED ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable effort has gone into investigating possible causes of CFS. Among the many possible precipitants, the ones that have been most thoroughly studied are viruses, immune dysfunction, endocrine-metabolic dysfunction, and neuropsychiatric factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been intense interest in whether certain viruses could be responsible for causing CFS, including Epstein-Barr virus (EBV), xenotropic murine leukemia virus-related virus (XMRV), and others. None has been proven to cause CFS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70034228\">",
"    <span class=\"h3\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBV received a great deal of attention in the mid-1980s as a possible etiologic agent for CFS. This hypothesis was based upon three observations. First, EBV persists for life and reactivates frequently, thereby affording the virus the biologic potential for chronic illness. Second, patients with CFS were often found to possess higher than expected titers of antibodies to EBV capsid and early antigens, or to lack antibodies to EBV nuclear antigens (EBNA), each suggestive of recent or active infection. Third, some patients clearly attributed the onset of their illness to a mononucleosis-like infection.",
"   </p>",
"   <p>",
"    However, later observations suggest that the proposed relation between EBV infection and CFS is not correct. The serologic profiles of patients with CFS are nonspecific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/7,32\">",
"     7,32",
"    </a>",
"    ]. One study, for example, found that EBV serologies were unable to distinguish between 15 patients with severe fatigue of unknown etiology for two months, and over 100 patients with less severe fatigue or completely healthy controls. In addition, most cases of CFS either evolve insidiously or follow influenza-like or gastroenteric-type illnesses rather than mononucleosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70034235\">",
"    <span class=\"h3\">",
"     Other viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to EBV, a number of other viruses have been proposed as the cause of CFS. These include retroviruses, human herpesvirus type 6 (HHV-6), enteroviruses, coxsackie B virus, Ross river virus, and Borna disease virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some observations regarding these viruses have included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies to these and other viruses were initially found to be more prevalent in patients with CFS than in controls. Subsequent studies, however, revealed only higher titers or irreproducible results in these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/32,33\">",
"       32,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Investigators in the United Kingdom reported detection of enteroviral RNA and proteins in the muscle tissue of patients with CFS who had pronounced myalgias [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another group reported detection of retroviral sequences of a virus related to human T-lymphotropic virus (HTLV) in patients with CFS using the polymerase chain reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, neither of the last two reports could be confirmed in other laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, a seroepidemiologic study from the CDC for over 40 different infectious agents failed to reveal an association with any particular organism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/37\">",
"     37",
"    </a>",
"    ]. Neither of two interferon-induced antiviral pathways was activated in patients with CFS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70034242\">",
"    <span class=\"h3\">",
"     XMRV and MLV",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA from the retrovirus xenotropic murine leukemia virus-related virus (XMRV) and related retroviruses, such as murine leukemia virus (MLV), was detected in the blood of some patients with CFS in two studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, XMRV was",
"    <strong>",
"     not",
"    </strong>",
"    detected in the blood of patients with CFS in several other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/39-43\">",
"     39-43",
"    </a>",
"    ], including studies that used the same blood samples as the earlier studies in which XMRV was detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/44\">",
"     44",
"    </a>",
"    ], or blood drawn from the same individuals who previously had positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/45\">",
"     45",
"    </a>",
"    ]. One of the original studies that reported the detection of XMRV in the blood of patients with CFS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/10\">",
"     10",
"    </a>",
"    ] was later partially retracted by the authors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/46\">",
"     46",
"    </a>",
"    ], and subsequently fully retracted by the editor of the journal in which it was published due to concerns about the validity of the results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/47\">",
"     47",
"    </a>",
"    ]. Soon after this full retraction occurred, the authors of the other original study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/11\">",
"     11",
"    </a>",
"    ] retracted their results as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most comprehensive investigation to date was a multilaboratory study in which blood was collected from 147 patients with CFS and 146 healthy individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/43\">",
"     43",
"    </a>",
"    ]. Samples were sent in a blinded fashion to three laboratories, including the two laboratories that initially reported detecting DNA from XMRV or MLV in the blood of patients with CFS and one of the laboratories that reported failure to replicate these findings. DNA from XMRV or MLV were not detected from the plasma or peripheral blood mononuclear cells of any of the patients with CFS or from any of the healthy patients.",
"   </p>",
"   <p>",
"    Importantly, multiple studies have demonstrated that contamination of patient samples (with mouse genomic DNA), laboratory reagents (with MLV-encoding nucleic acids), and human tumor cell lines (with XMRV or related viruses) can lead to the detection of these retroviruses, suggesting that the earlier findings that showed an association between CFS and XMRV or MLV were caused by contamination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/44,49-54\">",
"     44,49-54",
"    </a>",
"    ]. One study demonstrated that XMRV was generated by the recombination of two proviruses during passaging of a human prostate cancer xenograft in mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, a phylogenetic analysis of MLV sequences from samples that were collected longitudinally from CFS patients suggested that the MLV sequences were consistent with contamination rather than viral evolution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immune dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence of immune differences in patients with CFS relative to healthy control subjects, but the pathogenetic importance of these changes is not thought to be significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. These findings have led some to call CFS the chronic fatigue and immune dysfunction syndrome (CFIDS). Among the differences in immune markers seen in CFS are lower than normal levels of circulating immune complexes, reduced numbers of natural killer (NK) cells, depressed NK cell function, altered levels of immunoglobulins, elevated titers of antiviral antibodies (directed against measles, HHV-6, EBV, and cytomegalovirus), lower levels of autoantibodies, increased cell surface adhesion molecules, enhanced interferon activity, increased levels of interleukin-2, and altered",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratios.",
"   </p>",
"   <p>",
"    These observations raise the possibility that some cases of CFS are associated with a chronic inflammatory process. In one report of 147 individuals with CFS, for example, a reduced CD8 suppressor cell population and increased activation markers (CD38, HLA-DR) on CD8 cells were found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/56\">",
"     56",
"    </a>",
"    ]. These immunologic indices were not found in 80 healthy controls or 43 patients with other diseases. Another study of 259 patients with CFS found higher",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    T cell ratios compared with matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to appreciate, however, that the abnormalities noted in various studies have been diverse, modest, and in some cases conflicting. A true immune deficiency is not a feature of this syndrome, although there may be a mild immune dysregulation of uncertain pathogenetic importance. Furthermore, case-control studies have found no differences in white blood cell counts, immune complexes, complement, immunoglobulins, delayed hypersensitivity, allergic responses, natural killer cell function, cytokine levels, or proliferative responses to mitogens and antigens in patients with CFS compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endocrine-metabolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several metabolic abnormalities have been described in CFS, but their causal role is unclear. Low serum cortisol levels have been found in patients with CFS who met the CDC criteria; other data suggested chronic undersecretion of corticotropin-releasing hormone, perhaps as a reflection of an underlying neuroendocrine disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/64\">",
"     64",
"    </a>",
"    ]. There is also evidence suggesting that patients with CFS have increased serotoninergic activity in the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/65\">",
"     65",
"    </a>",
"    ], and enhanced serum levels of insulin-like growth factor I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some of these changes are not specific for CFS since similar neuroendocrine abnormalities are seen in patients with fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/67\">",
"     67",
"    </a>",
"    ], other syndromes with atypical depressive features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/68\">",
"     68",
"    </a>",
"    ], and after an alteration in sleep pattern in otherwise healthy subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/69\">",
"     69",
"    </a>",
"    ]. Furthermore, some studies have not confirmed a defect in the pituitary-adrenal axis in patients with CFS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neurally-mediated hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study suggested that neurally mediated hypotension might play an important role in CFS symptoms. In this report, 23 subjects with CFS underwent tilt table testing: 22 were found to have an abnormal test (compared with 4 of 14 unmatched controls) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/71\">",
"     71",
"    </a>",
"    ]. Those CFS patients with a positive test were treated with escalating doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    ; almost all reported complete or partial resolution of symptoms. In a subsequent study of 600 patients with CFS from the same investigators, 77 percent of patients were found to have an abnormal tilt table test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/72\">",
"     72",
"    </a>",
"    ]; however, no control group was mentioned.",
"   </p>",
"   <p>",
"    A group from Israel developed a hemodynamic instability score in association with tilt testing and found that patients with CFS had positive scores or were unable to complete the test due to changes in blood pressure or heart rate, while patients with other conditions, such as chronic fatigue that did not meet CFS definitions, fibromyalgia, neurally mediated syncope, familial hypertension and otherwise healthy subjects had negative scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/73\">",
"     73",
"    </a>",
"    ]. The study was not blinded and control patients were not matched with CFS subjects.",
"   </p>",
"   <p>",
"    Although these results appear intriguing, these early studies were not placebo-controlled, blinded, or randomized. A study in 21 pairs of monozygotic twins, in which one of the set had CFS and one did not, found abnormal tilt tests in 19 percent of those with CFS and 19 percent of those without [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/74\">",
"     74",
"    </a>",
"    ]. In addition, a preliminary blinded study of 20 individuals with CFS who had not undergone tilt table testing found that low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    (0.1 to 0.2 mg) did not provide any benefit compared with placebo after six weeks of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/75\">",
"     75",
"    </a>",
"    ]. Thus, the role of neurally-mediated hypotension in CFS is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is a theme that has pervaded the CFS literature for years. It is a charged issue that patients prefer to dismiss because of the personal and societal stigma attached to psychiatric diagnoses. Three studies verified that two-thirds or more of patients with CFS meet existing psychiatric criteria for anxiety disorders, dysthymia, or depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Among patients who develop viral illnesses, a subsequent mood disorder is predicted better by the psychiatric history preceding the infection, whereas fatigue correlates better with EBV infection and inversely with the patient's premorbid level of physical fitness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some interpret these findings as implying that the fatigue results from a psychiatric disorder; others argue that the psychiatric problems arise from the chronic fatigue and disability. It is reasonable to expect that a functioning, highly productive person who suddenly becomes an invalid might become depressed.",
"   </p>",
"   <p>",
"    A prospective study of patients with an acute viral type of illness found that a history of psychiatric morbidity, the patient's belief about viruses as the cause of their complaints, and how the clinician reinforced those beliefs could conspire to predict chronic fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/80\">",
"     80",
"    </a>",
"    ]. The infective symptoms predicted fatigue initially but not six months later, suggesting that CFS may be more related to premorbid characteristics of the patient and clinician behavior than to features of a precipitating viral illness.",
"   </p>",
"   <p>",
"    Even if depression is not the underlying cause but rather a consequence of CFS, it should be aggressively treated so that the patient can better manage CFS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sleep disruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disruption has been proposed as a possible cause of CFS. A small study showed that CFS patients had significant differences in polysomnographic findings and felt sleepier than controls after a night's sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/81\">",
"     81",
"    </a>",
"    ]. CFS patients had less total sleep time, lower sleep efficiency, and less rapid eye movement sleep than controls. The findings in the CFS group could neither be attributed to diagnosable sleep disorders nor to fibromyalgia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data generated from 227 patients with CFS who underwent detailed clinical evaluations, measurements of sleep physiology, cognitive function, autonomic nervous system function, and blood analyses of the sequence and expression of 20,000 genes have linked CFS to certain genes involved in immune and stress responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The following findings were noted in CFS patients compared with controls:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Different levels of expression of genes with roles in the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system; functionally these led to differences in how the body responds to hormones and other chemical messengers that are released in response to challenges and stressors such as trauma, injury, and other adverse events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DNA sequence changes in three genes associated with brain function, stress reactions, and emotional responses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings suggest that difficulty managing stress may be linked to the development of CFS. They also suggest that there is not a single cause of CFS, but that there may be a number of stress-related triggers in those with a genetic predisposition. These studies are the strongest evidence for a biologic basis for CFS and may help to more effectively diagnose and develop effective treatments for this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic fatigue syndrome (CFS) is not a homogeneous disorder, but there are certain clinical features, which are common and important to recognize:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relatively sudden onset of fatigue, often associated with a typical infection such as an upper respiratory infection or true mononucleosis.",
"     </li>",
"     <li>",
"      After resolution of the initial infection, the patient is left with overwhelming fatigue and a number of additional symptoms, especially altered sleep and cognition.",
"     </li>",
"     <li>",
"      Excessive physical activity characteristically exacerbates the symptoms.",
"     </li>",
"     <li>",
"      The pre-CFS medical history of the patient is not one of multiple somatic problems such as chronic backache or chronic headache. Affected patients are typically highly functioning individuals who are \"struck down\" with this disease. There is often, however, a history of psychiatric disorders in the past [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/84,85\">",
"       84,85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous other subjective features of CFS fluctuate with time but do not appear to progress (",
"    <a class=\"graphic graphic_table graphicRef77546 \" href=\"mobipreview.htm?5/15/5372\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the inciting illness (if any) is resolved, the physical examination typically is normal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although patients commonly feel febrile, few ever demonstrate elevated temperatures (greater than 37.4&ordm;C).",
"     </li>",
"     <li>",
"      Joints ache, but there is no erythema, effusion, or limitation of motion.",
"     </li>",
"     <li>",
"      Although the muscles are easily fatigued, strength is normal, as are biopsies and electromyograms.",
"     </li>",
"     <li>",
"      Mild cervical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      axillary lymphadenitis is occasionally noted, and painful lymph nodes (lymphadenia) are a frequent complaint, but not true lymphadenopathy. Biopsied lymph nodes show only reactive hyperplasia. The cervical lymph nodes are involved most commonly, but the axillary lymph nodes may also be affected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients with chronic fatigue syndrome are partially or totally disabled by its manifestations. Their outward, healthy appearance belies the internal sense of ill health. It is common for relatives and colleagues to accuse them of malingering. A vicious cycle of frustration, anger, and depression commonly ensues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little published information about CFS in pregnancy. However, a survey of 86 women who had 252 pregnancies before and after a diagnosis of CFS was generally reassuring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/86\">",
"     86",
"    </a>",
"    ]. Approximately one-third of patients reported no change, improvement or worsening of their symptoms both during and after pregnancy. Pregnancy outcomes were similar before and after the onset of CFS when compared with a large Danish population-based survey. Although these data are the best available at this time, participation in the survey was only 63 percent; there was no healthy comparison group; and the results were based on self-reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention and the International Chronic Fatigue Syndrome Study Group published guidelines in 1994 regarding the standard evaluation in a patient suspected of having CFS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with CFS must have clinically evaluated, unexplained, persistent, or relapsing fatigue plus four or more specifically defined associated symptoms (",
"    <a class=\"graphic graphic_table graphicRef55495 \" href=\"mobipreview.htm?34/8/34955\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After a thorough history and physical examination, the patient is asked to keep temperature and weight records and limited laboratory testing is performed including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential count",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate",
"     </li>",
"     <li>",
"      Chemistry screen",
"     </li>",
"     <li>",
"      Thyroid stimulating hormone level",
"     </li>",
"     <li>",
"      Other tests when clinically indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Expensive immunologic tests and serologies are not useful. We do not routinely perform serologies for EBV, CMV, or Lyme disease, or test for antinuclear antibodies. In the setting of low pretest probability, any positive test is likely to be a false positive result, which may complicate the evaluation. Specific additional tests may be indicated to assess a particular issue in the patient's history and presentation.",
"   </p>",
"   <p>",
"    The diagnosis of CFS is one of exclusion. It is generally made if the patient has a typical history, and no abnormality can be detected on physical examination or in the screening tests. We do not perform expensive neuroimaging. MR imaging and SPECT scan abnormalities seem to occur more frequently in patients with CFS than in controls; however, these findings are of unknown significance and do not warrant a change in diagnosis or management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/58,87\">",
"     58,87",
"    </a>",
"    ]. As noted above, well under 10 percent of patients with chronic fatigue have CFS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30825/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of chronic fatigue includes many disorders and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23111?source=see_link\">",
"     \"Approach to the adult patient with fatigue\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/47/4850?source=see_link\">",
"       \"Patient information: Chronic fatigue syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/11/42161?source=see_link\">",
"       \"Patient information: Chronic fatigue syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The chronic fatigue syndrome (CFS) has received considerable attention but remains a complicated and controversial disease. Much of this is due to the lack of objective findings. Nonetheless, patients with CFS have real symptoms and are not malingerers. The prevalence of this syndrome is unclear in part due to difficulties in proving the diagnosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CFS is associated with the following groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is primarily a disorder of young to middle aged adults.",
"     </li>",
"     <li>",
"      CFS is about twice as common in women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Few cases have been reported in minorities or among lower socioeconomic groups. However, the incidence in these groups may be underestimated due to their lack of equivalent access to health care institutions in which CFS is studied. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There has been intense interest in whether certain viruses could be responsible for causing CFS, including Epstein-Barr virus (EBV), xenotropic murine leukemia virus-related virus (XMRV), and others. None has been proven to cause CFS. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is evidence of immune differences in patients with CFS relative to healthy control subjects, but the pathogenetic importance of these changes is not thought to be significant. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immune dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several metabolic abnormalities have been described in CFS, but their causal role is unclear. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Endocrine-metabolic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression is a theme that has pervaded the CFS literature for years. It is a charged issue that patients prefer to dismiss because of the personal and societal stigma attached to psychiatric diagnoses. Two-thirds or more of patients with CFS meet existing psychiatric criteria for anxiety disorders, dysthymia, or depression. Even if this is not the underlying cause but rather a consequence of CFS, it should be aggressively treated so that the patient can better manage CFS. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CFS is not a homogeneous disorder, but there are certain clinical features, which are common and important to recognize:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Relatively sudden onset of fatigue, often associated with a typical infection such as an upper respiratory infection or true mononucleosis.",
"     </li>",
"     <li>",
"      After resolution of the initial infection, the patient is left with overwhelming fatigue and a number of additional symptoms, especially altered sleep and cognition.",
"     </li>",
"     <li>",
"      Excessive physical activity characteristically exacerbates the symptoms.",
"     </li>",
"     <li>",
"      The pre-CFS medical history of the patient is not one of multiple somatic problems such as chronic backache or chronic headache. Affected patients are typically highly functioning individuals who are \"struck down\" with this disease.",
"     </li>",
"     <li>",
"      Numerous other subjective features of CFS fluctuate with time but do not appear to progress (",
"      <a class=\"graphic graphic_table graphicRef77546 \" href=\"mobipreview.htm?5/15/5372\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Once the inciting illness (if any) is resolved, the physical examination typically is normal. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To meet the definition of CFS made by the United States Centers for Disease Control and Prevention and an international study group, patients must have clinically evaluated, unexplained, persistent or relapsing fatigue plus four or more specifically defined associated symptoms (",
"      <a class=\"graphic graphic_table graphicRef55495 \" href=\"mobipreview.htm?34/8/34955\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After a thorough history and physical examination, the patient is asked to keep temperature and weight records and limited laboratory testing is performed including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete blood count with differential count",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate",
"     </li>",
"     <li>",
"      Chemistry screen",
"     </li>",
"     <li>",
"      Thyroid stimulating hormone level",
"     </li>",
"     <li>",
"      Other tests when clinically indicated (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of CFS is one of exclusion. It is generally made if the patient has a typical history, and no abnormality can be detected on physical examination or in the screening tests. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/1\">",
"      Prins JB, van der Meer JW, Bleijenberg G. Chronic fatigue syndrome. Lancet 2006; 367:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/2\">",
"      Bates DW, Schmitt W, Buchwald D, et al. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med 1993; 153:2759.",
"     </a>",
"    </li>",
"    <li>",
"     Aronowitz RA. From myalgic encephalitis to yuppie flu: A history of chronic fatigue syndromes. In: Framing Disease, Rosenberg CE, Golden J (Eds), Rutgers University Press, New Brunswick, NJ 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/4\">",
"      Kim E. A brief history of chronic fatigue syndrome. JAMA 1994; 272:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/5\">",
"      Jones JF, Ray CG, Minnich LL, et al. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med 1985; 102:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/6\">",
"      Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985; 102:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/7\">",
"      Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988; 157:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/8\">",
"      Simon GE, Daniell W, Stockbridge H, et al. Immunologic, psychological, and neuropsychological factors in multiple chemical sensitivity. A controlled study. Ann Intern Med 1993; 119:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/9\">",
"      Renfro L, Feder HM Jr, Lane TJ, et al. Yeast connection among 100 patients with chronic fatigue. Am J Med 1989; 86:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/10\">",
"      Lombardi VC, Ruscetti FW, Das Gupta J, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009; 326:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/11\">",
"      Lo SC, Pripuzova N, Li B, et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A 2010; 107:15874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/12\">",
"      Working Group of the Royal Australasian College of Physicians. Chronic fatigue syndrome. Clinical practice guidelines--2002. Med J Aust 2002; 176 Suppl:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/13\">",
"      Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/14\">",
"      Schluederberg A, Straus SE, Peterson P, et al. NIH conference. Chronic fatigue syndrome research. Definition and medical outcome assessment. Ann Intern Med 1992; 117:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/15\">",
"      Goldenberg DL, Simms RW, Geiger A, Komaroff AL. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum 1990; 33:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/16\">",
"      Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 1994; 154:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/17\">",
"      Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000; 160:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/18\">",
"      Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/19\">",
"      Nishikai M, Akiya K, Tojo T, et al. 'Seronegative' Sj&ouml;gren's syndrome manifested as a subset of chronic fatigue syndrome. Br J Rheumatol 1996; 35:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/20\">",
"      Calabrese LH, Davis ME, Wilke WS. Chronic fatigue syndrome and a disorder resembling Sj&ouml;gren's syndrome: preliminary report. Clin Infect Dis 1994; 18 Suppl 1:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/21\">",
"      Sirois DA, Natelson B. Clinicopathological findings consistent with primary Sj&ouml;gren's syndrome in a subset of patients diagnosed with chronic fatigue syndrome: preliminary observations. J Rheumatol 2001; 28:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/22\">",
"      Kroenke K, Wood DR, Mangelsdorff AD, et al. Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. JAMA 1988; 260:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/23\">",
"      Reyes M, Nisenbaum R, Hoaglin DC, et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. Arch Intern Med 2003; 163:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/24\">",
"      Wessely S, Chalder T, Hirsch S, et al. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study. Am J Public Health 1997; 87:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/25\">",
"      Patel V, Kirkwood BR, Weiss H, et al. Chronic fatigue in developing countries: population based survey of women in India. BMJ 2005; 330:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/26\">",
"      Buchwald D, Umali P, Umali J, et al. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. Ann Intern Med 1995; 123:81.",
"     </a>",
"    </li>",
"    <li>",
"     Gilliam AG. Epidemiologic study of an epidemic diagnosed as poliomyelitis, occurring among personnel of Los Angeles County General Hospital during the summer of 1934: Bull no 240. Institute of Health; US Public Health Service, Division of Infectious Diseases, Washington, DC 1938.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/28\">",
"      ACHESON ED. The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia. Am J Med 1959; 26:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/29\">",
"      HENDERSON DA, SHELOKOV A. Epidemic neuromyasthenia; clinical syndrome. N Engl J Med 1959; 260:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/30\">",
"      AN OUTBREAK of encephalomyelitis in the Royal Free Hospital Group, London, in 1955. Br Med J 1957; 2:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/31\">",
"      Levine PH, Dale JK, Benson-Grigg E, et al. A cluster of cases of chronic fatigue and chronic fatigue syndrome: clinical and immunologic studies. Clin Infect Dis 1996; 23:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/32\">",
"      Holmes GP, Kaplan JE, Stewart JA, et al. A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause? JAMA 1987; 257:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/33\">",
"      Ablashi DV, Josephs SF, Buchbinder A, et al. Human B-lymphotropic virus (human herpesvirus-6). J Virol Methods 1988; 21:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/34\">",
"      Archard LC, Bowles NE, Behan PO, et al. Postviral fatigue syndrome: persistence of enterovirus RNA in muscle and elevated creatine kinase. J R Soc Med 1988; 81:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/35\">",
"      DeFreitas E, Hilliard B, Cheney PR, et al. Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci U S A 1991; 88:2922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/36\">",
"      Khan AS, Heneine WM, Chapman LE, et al. Assessment of a retrovirus sequence and other possible risk factors for the chronic fatigue syndrome in adults. Ann Intern Med 1993; 118:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/37\">",
"      Mawle AC, Nisenbaum R, Dobbins JG, et al. Seroepidemiology of chronic fatigue syndrome: a case-control study. Clin Infect Dis 1995; 21:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/38\">",
"      Gow JW, Simpson K, Behan PO, et al. Antiviral pathway activation in patients with chronic fatigue syndrome and acute infection. Clin Infect Dis 2001; 33:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/39\">",
"      Henrich TJ, Li JZ, Felsenstein D, et al. Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis 2010; 202:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/40\">",
"      Erlwein O, Kaye S, McClure MO, et al. Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One 2010; 5:e8519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/41\">",
"      van Kuppeveld FJ, de Jong AS, Lanke KH, et al. Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ 2010; 340:c1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/42\">",
"      Groom HC, Boucherit VC, Makinson K, et al. Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/43\">",
"      Alter HJ, Mikovits JA, Switzer WM, et al. A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus. MBio 2012; 3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/44\">",
"      Knox K, Carrigan D, Simmons G, et al. No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science 2011; 333:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/45\">",
"      Simmons G, Glynn SA, Komaroff AL, et al. Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 2011; 334:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/46\">",
"      Silverman RH, Das Gupta J, Lombardi VC, et al. Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2011; 334:176.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.sciencemag.org/content/334/6063/1636.1.full (Accessed on December 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/48\">",
"      Lo SC, Pripuzova N, Li B, et al. Retraction for Lo et al., Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A 2012; 109:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/49\">",
"      Hu&eacute; S, Gray ER, Gall A, et al. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology 2010; 7:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/50\">",
"      Oakes B, Tai AK, Cing&ouml;z O, et al. Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology 2010; 7:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/51\">",
"      Smith RA. Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology 2010; 7:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/52\">",
"      Hurlburt WB. Linitis plastica in a 16-year-old. Alaska Med 1975; 17:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/53\">",
"      Gupta GS, Bawa SR. Radiation effects on rat testes. V. Studies on lysosomal enzymes (acid phosphatase and acid DNAse) and their physiological significance following partial body gamma-irradiation. J Reprod Fertil 1975; 44:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/54\">",
"      Paprotka T, Delviks-Frankenberry KA, Cing&ouml;z O, et al. Recombinant origin of the retrovirus XMRV. Science 2011; 333:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/55\">",
"      Katzourakis A, Hu&eacute; S, Kellam P, Towers GJ. Phylogenetic analysis of murine leukemia virus sequences from longitudinally sampled chronic fatigue syndrome patients suggests PCR contamination rather than viral evolution. J Virol 2011; 85:10909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/56\">",
"      Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991; 338:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/57\">",
"      Klonoff DC. Chronic fatigue syndrome. Clin Infect Dis 1992; 15:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/58\">",
"      Buchwald D, Cheney PR, Peterson DL, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 1992; 116:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/59\">",
"      Nishikai M, Tomomatsu S, Hankins RW, et al. Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hypersomnia and cognitive disorders. Rheumatology (Oxford) 2001; 40:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/60\">",
"      Vernon SD, Reeves WC. Evaluation of autoantibodies to common and neuronal cell antigens in Chronic Fatigue Syndrome. J Autoimmune Dis 2005; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/61\">",
"      Mawle AC, Nisenbaum R, Dobbins JG, et al. Immune responses associated with chronic fatigue syndrome: a case-control study. J Infect Dis 1997; 175:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/62\">",
"      Natelson BH, LaManca JJ, Denny TN, et al. Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis. Am J Med 1998; 105:43S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/63\">",
"      Vollmer-Conna U, Cameron B, Hadzi-Pavlovic D, et al. Postinfective fatigue syndrome is not associated with altered cytokine production. Clin Infect Dis 2007; 45:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/64\">",
"      Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 73:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/65\">",
"      Sharpe M, Hawton K, Clements A, Cowen PJ. Increased brain serotonin function in men with chronic fatigue syndrome. BMJ 1997; 315:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/66\">",
"      Bennett AL, Mayes DM, Fagioli LR, et al. Somatomedin C (insulin-like growth factor I) levels in patients with chronic fatigue syndrome. J Psychiatr Res 1997; 31:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/67\">",
"      Crofford LJ, Pillemer SR, Kalogeras KT, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994; 37:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/68\">",
"      Joseph-Vanderpool JR, Rosenthal NE, Chrousos GP, et al. Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. J Clin Endocrinol Metab 1991; 72:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/69\">",
"      Leese G, Chattington P, Fraser W, et al. Short-term night-shift working mimics the pituitary-adrenocortical dysfunction in chronic fatigue syndrome. J Clin Endocrinol Metab 1996; 81:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/70\">",
"      Young AH, Sharpe M, Clements A, et al. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia). Biol Psychiatry 1998; 43:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/71\">",
"      Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/72\">",
"      Rowe PC, Calkins H. Neurally mediated hypotension and chronic fatigue syndrome. Am J Med 1998; 105:15S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/73\">",
"      Naschitz JE, Rosner I, Rozenbaum M, et al. The head-up tilt test with haemodynamic instability score in diagnosing chronic fatigue syndrome. QJM 2003; 96:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/74\">",
"      Poole J, Herrell R, Ashton S, et al. Results of isoproterenol tilt table testing in monozygotic twins discordant for chronic fatigue syndrome. Arch Intern Med 2000; 160:3461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/75\">",
"      Peterson PK, Pheley A, Schroeppel J, et al. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med 1998; 158:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/76\">",
"      Taerk GS, Toner BB, Salit IE, et al. Depression in patients with neuromyasthenia (benign myalgic encephalomyelitis). Int J Psychiatry Med 1987; 17:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/77\">",
"      Kruesi MJ, Dale J, Straus SE. Psychiatric diagnoses in patients who have chronic fatigue syndrome. J Clin Psychiatry 1989; 50:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/78\">",
"      Manu P, Lane TJ, Matthews DA. The frequency of the chronic fatigue syndrome in patients with symptoms of persistent fatigue. Ann Intern Med 1988; 109:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/79\">",
"      White PD, Thomas JM, Kangro HO, et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. Lancet 2001; 358:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/80\">",
"      Cope H, David A, Pelosi A, Mann A. Predictors of chronic \"postviral\" fatigue. Lancet 1994; 344:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/81\">",
"      Togo F, Natelson BH, Cherniack NS, et al. Sleep structure and sleepiness in chronic fatigue syndrome with or without coexisting fibromyalgia. Arthritis Res Ther 2008; 10:R56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/82\">",
"      Smith AK, White PD, Aslakson E, et al. Polymorphisms in genes regulating the HPA axis associated with empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics 2006; 7:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/83\">",
"      Goertzel BN, Pennachin C, de Souza Coelho L, et al. Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. Pharmacogenomics 2006; 7:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/84\">",
"      Katon WJ, Buchwald DS, Simon GE, et al. Psychiatric illness in patients with chronic fatigue and those with rheumatoid arthritis. J Gen Intern Med 1991; 6:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/85\">",
"      Lane TJ, Manu P, Matthews DA. Depression and somatization in the chronic fatigue syndrome. Am J Med 1991; 91:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/86\">",
"      Schacterle RS, Komaroff AL. A comparison of pregnancies that occur before and after the onset of chronic fatigue syndrome. Arch Intern Med 2004; 164:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30825/abstract/87\">",
"      Schwartz RB, Garada BM, Komaroff AL, et al. Detection of intracranial abnormalities in patients with chronic fatigue syndrome: comparison of MR imaging and SPECT. AJR Am J Roentgenol 1994; 162:935.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2740 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30825=[""].join("\n");
var outline_f30_6_30825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROPOSED ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70034228\">",
"      - Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70034235\">",
"      - Other viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70034242\">",
"      - XMRV and MLV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immune dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endocrine-metabolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neurally-mediated hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sleep disruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2740\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2740|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/0/10252\" title=\"table 1\">",
"      Diagnostic criteria for CFS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/57/16283\" title=\"table 2\">",
"      Sx fibromyalgia chronic fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/8/34955\" title=\"table 3\">",
"      Revised diagnostic criteria CFS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/15/5372\" title=\"table 4\">",
"      Symptoms of CFS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23111?source=related_link\">",
"      Approach to the adult patient with fatigue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/11/42161?source=related_link\">",
"      Patient information: Chronic fatigue syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/47/4850?source=related_link\">",
"      Patient information: Chronic fatigue syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4440?source=related_link\">",
"      Treatment of chronic fatigue syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_6_30826="Cardiovascular sequelae of Kawasaki disease";
var content_f30_6_30826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiovascular sequelae of Kawasaki disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30826/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30826/contributors\">",
"     Jane W Newburger, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30826/contributors\">",
"     Sarah D de Ferranti, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30826/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30826/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/6/30826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/6/30826/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/6/30826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13231710\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease (KD), also called mucocutaneous lymph node syndrome, first described by Dr. Tomisako Kawasaki in 1967, is a vasculitis of unknown etiology that generally occurs in infancy and childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/1\">",
"     1",
"    </a>",
"    ]. The acute illness is self-limited and is characterized by high fever, nonexudative conjunctivitis, inflammation of the oral mucosa, rash, cervical adenopathy, and findings in the extremities, including swollen hands and feet, red palms and soles, and, later, subungual peeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately one in five patients who are not treated early in the disease with high-dose intravenous gamma globulin (IVIG) develops coronary artery aneurysms, which can lead to myocardial ischemia, infarction, and sudden death. As a result, initial management of patients with KD is focused on early diagnosis and treatment with IVIG.",
"   </p>",
"   <p>",
"    The cardiac sequelae of KD including coronary artery aneurysms and their management will be reviewed here. The epidemiology, etiology, clinical manifestations, diagnosis, and initial treatment of KD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=see_link\">",
"     \"Kawasaki disease: Epidemiology and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42025?source=see_link\">",
"     \"Kawasaki disease: Initial treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231717\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular histopathology has been described in only a few small autopsy series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], as mortality is rare in the current era of treatment with IVIG (in-hospital mortality in the United States ranges from 0 to 0.17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]). In these studies, early KD is manifested as a pan-arteritis without fibrinoid necrosis. Infiltration of inflammatory cells (ie, neutrophils, lymphocytes, macrophages, and plasma cells) leads to dissociation and disruption of the media and internal elastic lamina. Studies using immunohistochemical techniques demonstrate that neutrophil infiltration in the coronary arterial wall peaks prior to infiltrations of CD68+",
"    <span class=\"nowrap\">",
"     monocytes/macrophages,",
"    </span>",
"    CD3+ lymphocytes, and CD20+ lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the vasculitis, which affects the coronary arteries, cardiac involvement during the acute phase of KD includes inflammation in the pericardium, myocardium, atrioventricular conduction system, heart valves, and endocardium. Fulminant myocarditis and arrhythmias were reported to cause early deaths among the initial reported case series of KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition to data from autopsy series, which are skewed to the most severe cases, right ventricular endomyocardial biopsies have suggested that myocarditis is common, with late persistence of myocyte hypertrophy, disarray, and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autopsy studies of deaths occurring one month after onset of disease (ie, convalescent phase) show progressive neointimal proliferation, neoangiogenesis, and fibrosis with scar formation, whereas autopsies among patients who die several years later after the diagnosis of KD typically show severe coronary artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The late coronary artery histology among patients with aneurysms is characterized by replacement of medial smooth muscle with fibroblasts and extracellular matrix, and destruction of the internal elastic lamina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/10\">",
"     10",
"    </a>",
"    ]. Growth factors are expressed at areas of high sheer stress, such as the inlet and outlet of aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/11\">",
"     11",
"    </a>",
"    ]. The late histopathology in KD differs from that described in routine adult atherosclerotic heart disease. As a result, the natural history and responses to coronary interventions in KD cannot be directly extrapolated from the large adult coronary literature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231724\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the acute phase, cardiac manifestations include tachycardia out of proportion to the degree of fever, a hyperdynamic precordium, and a gallop rhythm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because most children are anemic and febrile at presentation, innocent flow murmurs are usually present. One quarter of patients during the acute phase of KD have mitral regurgitation that may be detected by a regurgitant murmur at the apex. This mitral regurgitation in acute KD generally results from valvulitis, whereas late mitral regurgitation is more likely to reflect papillary muscle dysfunction associated with ischemic heart disease. Infrequently, patients may present with low cardiac output and shock, mimicking viral-induced acute fulminant myocarditis. Rarely, KD can present with hemophagocytic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16183?source=see_link&amp;anchor=H5036611#H5036611\">",
"     \"Kawasaki disease: Complications\", section on 'Macrophage activation syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16183?source=see_link&amp;anchor=H2507746#H2507746\">",
"     \"Kawasaki disease: Complications\", section on 'Shock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants less than six months of age may be particularly ill at presentation. Some have cold, pale, or cyanotic digits of the hands and feet with reduced blood perfusion. Peripheral gangrene may, in rare cases, cause loss of fingers or toes during this acute period. Finally, young infants may develop fusiform aneurysms of the brachial arteries, which are palpable or visible in the axillae.",
"   </p>",
"   <p>",
"    Late manifestations of KD are restricted to cardiac symptoms and events, which occur solely in patients who had coronary artery disease. This was illustrated in a long-term study that provided indirect evidence using coronary arterial calcification, which showed coronary artery calcium scores were normal more than 10 years after onset of KD among patients who always had normal coronary artery diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, coronary calcification ranged from mild to severe in 10 of 14 patients with initial coronary aneurysm at follow-up.",
"   </p>",
"   <p>",
"    In the convalescent and late phases of KD, patients with significant coronary disease are often asymptomatic. Those with large or giant coronary aneurysms who present with the following findings need to be emergently evaluated because they are at-risk for ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angina (more common in older children)",
"     </li>",
"     <li>",
"      Abdominal pain or vomiting occurring outside the context of a viral syndrome and in association with pallor and diaphoresis",
"     </li>",
"     <li>",
"      Inconsolable crying without obvious cause",
"     </li>",
"     <li>",
"      Episodes of syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a Japanese cross-sectional survey, symptoms during acute myocardial infarction were not detected in more than one third of patients, and the diagnosis was later identified by electrocardiographic abnormalities indicative of infarction [16]. (See",
"    <a class=\"local\" href=\"#H13231787\">",
"     'Myocardial infarction and coronary thrombosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children without coronary aneurysms during the acute or subacute phase are extremely unlikely to have ischemia or other late cardiac manifestations. The rates of non-cardiac diseases in individuals who have had KD are similar to those in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242696497\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major complication of KD is coronary artery aneurysms, which may result in myocardial ischemia, myocardial infarction, and sudden death. Other cardiovascular complications include decreased myocardial function in the acute phase, valvular regurgitation, pericardial effusion, and peripheral artery aneurysms [18]. Infants younger than one year of age with KD have the highest risk of developing cardiac complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242696532\">",
"    <span class=\"h2\">",
"     Coronary artery aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery aneurysm (CAA) is the most serious complication of KD. Coronary artery thrombosis and progressive stenosis within the aneurysm may cause late ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Indeed, &ldquo;missed&rdquo; KD in childhood can present with myocardial infarction in adulthood. CAA can first be detected by echocardiography about seven days after fever onset. In a retrospective review of 100 children treated for KD from a single tertiary center in the United States, including those with late presentation, 43 percent had a CA abnormality on their initial echocardiogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/21\">",
"     21",
"    </a>",
"    ]. Coronary ectasia was seen in 31 percent of patients and CAA in 13 percent.",
"   </p>",
"   <p>",
"    CAAs are located in the epicardial coronary arteries, most commonly in the proximal left anterior descending and proximal right coronary arteries, followed in frequency by the left main coronary artery, circumflex coronary artery, distal right coronary artery, and at the take-off of the posterior descending coronary artery from the right coronary artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/22\">",
"     22",
"    </a>",
"    ]. The predilection for CAAs at branch points suggests a pathologic role for sheer stress.",
"   </p>",
"   <p>",
"    CAAs can be saccular, fusiform, or ectatic (diffusely dilated without a segmental aneurysm) in shape, and their shape and size evolve over time. For example, an aneurysm that first appears to be ectatic can evolve to a segmented or beaded shape over weeks. The prognosis of CAAs depends on the size and shape of the aneurysm. The best prognosis is associated with small aneurysm size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, giant CAAs, with an internal diameter &gt;8 mm or with a z score &ge;+10, have the highest risk of morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/24\">",
"     24",
"    </a>",
"    ]. Up to one-third of such aneurysms become obstructed, and are associated with myocardial infarction, arrhythmias, or sudden death. (See",
"    <a class=\"local\" href=\"#H13231738\">",
"     'Echocardiography'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13231787\">",
"     'Myocardial infarction and coronary thrombosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13231794\">",
"     'Coronary revascularization procedures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single-center review of 76 children with Kawasaki disease and giant aneurysms (defined as &ge;8 mm in diameter) treated between 1972 and 2011 in Japan and observed over a median of 19 years, survival rates were 95 and 88 percent at 10 and 20 years, respectively, after KD onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/20\">",
"       20",
"      </a>",
"      ]. Cumulative rates of coronary intervention (surgical or percutaneous) were 28 percent, 43 percent, and 59 percent at 5, 15, and 25 years, respectively. These data should be interpreted in light of the limitations of a single-center retrospective study with selection bias (eg, patients had to have survived to the first cardiac catheterization), small sample size, and changing patient management over nearly four decades.",
"     </li>",
"     <li>",
"      In a multi-center study of 1975 cases of KD treated between 1976 (pre-IVIG era) and 2008 in the province of Quebec, 38 patients with giant aneurysms (defined as &ge;8 mm in diameter) were identified, including two cases detected at autopsy (1.9 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/25\">",
"       25",
"      </a>",
"      ]. At a mean follow-up of 9.3 years, the survival rate was 85 percent, and the risks of coronary thrombi and coronary intervention were 36 and 32 percent for these patients with giant aneurysms. All but one fatality occurred in the first year after disease onset.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients who develop aneurysms, mortality is highest between 15 and 45 days after onset of KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/17\">",
"     17",
"    </a>",
"    ]. Because coronary artery thrombosis is the leading cause of death in KD, medications to prevent thrombosis form the cornerstone of therapy for patients with aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13231780\">",
"     'Prevention of coronary thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Late diagnosis and treatment with IVIG is the most important modifiable risk factor associated with CAAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/26\">",
"     26",
"    </a>",
"    ]. Other reported risk factors at presentation include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/27-41\">",
"     27-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age younger than one year and older than nine years. Infants, particularly those under age six months, have the highest risk of aneurysms, even with prompt IVIG treatment. In addition, the frequent presentation with atypical disease in the youngest infants leads to delayed diagnosis and treatment. Older children also are at higher risk for coronary aneurysms; it is unclear whether older patients have an increased susceptibility to coronary artery dilation or whether the increased risk of CAA is primarily due to a delay in administration of IVIG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/42\">",
"       42",
"      </a>",
"      ]. IVIG treatment administered during the first 10 days of illness reduces the prevalence of CAAs fivefold [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/32,43\">",
"       32,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Male sex.",
"     </li>",
"     <li>",
"      Longer duration of fever.",
"     </li>",
"     <li>",
"      Failure to respond to initial IVIG therapy manifested by persistent and recrudescent fever. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42025?source=see_link&amp;anchor=H13#H13\">",
"       \"Kawasaki disease: Initial treatment and prognosis\", section on 'Refractory KD'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of refractory Kawasaki disease\", section on 'Incidence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laboratory findings that include lower hematocrit (ie, less than 35 percent) or hemoglobin, lower serum albumin, lower serum sodium (ie, &lt;135",
"      <span class=\"nowrap\">",
"       mEq/L),",
"      </span>",
"      higher alanine aminotransferase, elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), lower baseline serum IgG, and elevations in IL-6 and IL-8 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/30-33\">",
"       30-33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic polymorphisms including matrix metalloproteinase haplotypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/44\">",
"       44",
"      </a>",
"      ], and endothelial growth factor and its receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, the risk of CAAs appears to vary among ethnic groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report based upon national Kawasaki syndrome surveillance data from 1994 to 2003 that identified 3115 children with KD, Asian and Pacific Islander race and Hispanic ethnicity were associated with an increased risk of CAAs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis from the Pediatric Health Information System that identified 4811 patients with KD from 2001 to 2006, the highest rate of CAAs was reported in American Indians, but the number of such patients with KD was small [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/34\">",
"       34",
"      </a>",
"      ]. The second highest rate of CAAs was in Hispanics (5.9 percent), followed by white non-Hispanic patients (3.4 percent), and the lowest rates were seen in black and Asian patients (1.8 percent in both groups).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242698581\">",
"    <span class=\"h3\">",
"     Natural course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural course of CAAs is determined in large part by the severity of coronary artery disease during the acute phase of KD. Aneurysms may increase in size over the first four to six weeks after illness onset. After reaching a peak diameter, approximately 50 percent of aneurysmal segments regress to normal lumen diameter in the ensuing two years after the initial onset of KD; after this time, further regression generally does not occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/24,46\">",
"     24,46",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    The likelihood that an aneurysm will regress to normal lumen diameter is most strongly related to its maximum diameter; giant aneurysms are least likely to regress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Aneurysms are also more likely to regress in younger children, at more distal location, or those that are fusiform in shape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although internal lumen diameter is normal in regressed aneurysmal segments, myointimal thickening is evident by late intravascular ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]",
"    <sup>",
"    </sup>",
"    and is directly related to the initial coronary diameter during the early months after disease onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/50\">",
"     50",
"    </a>",
"    ]. Multiple studies have also demonstrated impaired coronary and peripheral vascular reactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/51-54\">",
"     51-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with persistent aneurysms, myointimal proliferation at the aneurysm entrance or exit progresses steadily over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/24,55,56\">",
"     24,55,56",
"    </a>",
"    ]. Approximately half of aneurysms of maximum diameter &ge;6 mm developed stenoses by 15 years follow-up in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/57\">",
"     57",
"    </a>",
"    ]. Aneurysmal arterial segments are also prone to increased tortuosity, calcification, and thrombotic occlusion. Because the arterial wall calcifies over time, the very rare event of aneurysm rupture is generally confined to the earliest months after illness onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242697570\">",
"    <span class=\"h2\">",
"     Myocardial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the acute phase of KD, depressed myocardial contractility may be caused by myocarditis, whereas ischemic cardiomyopathy may occur in patients after myocardial infarction. In a study of 198 patients with KD, echocardiographic evaluation demonstrated left ventricular dysfunction (ie, left ventricular fractional shortening with a z score &lt;-2) in 20 percent of patients at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/58\">",
"     58",
"    </a>",
"    ]. Myocardial function generally improved rapidly after IVIG administration, and systolic function normalized among patients without ischemic myocardial disease. However, patients with left ventricular dysfunction were more likely to have coronary artery dilation one and five weeks after diagnosis. The left ventricular dysfunction is due to impairment of both load-independent and load-independent measures of left ventricular contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/59\">",
"     59",
"    </a>",
"    ]. In analyses of diastolic function, relaxation has been found to be impaired during acute KD, and such abnormalities were seen long-term among patients with coronary aneurysms even in the absence of systolic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depressed myocardial contractility may progress to heart failure during the acute illness, and is often manifested by a S3 gallop, which may become more prominent with hydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242698055\">",
"    <span class=\"h2\">",
"     Valvular regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral regurgitation of mild or moderate severity is present in approximately one quarter of patients at baseline echocardiographic evaluation, with the incidence diminishing in the convalescent phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/58\">",
"     58",
"    </a>",
"    ]. Aortic regurgitation is reported, but is less common, occurring in approximately 1 percent of patients during the first five weeks of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/58\">",
"     58",
"    </a>",
"    ]. Mild aortic root dilation is common in the first three weeks of the disease and persists during the first year of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/58,62\">",
"     58,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242698174\">",
"    <span class=\"h2\">",
"     Pericardial effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial effusions of greater than 1 mm occur in fewer than 5 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/58\">",
"     58",
"    </a>",
"    ], although rare patients can develop pericardial tamponade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/63\">",
"     63",
"    </a>",
"    ]. Tamponade can also be a complication of rupture of a giant aneurysm into the pericardial space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242697681\">",
"    <span class=\"h2\">",
"     Noncoronary vascular involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aneurysms can occur in peripheral medium-sized, muscular, extraparenchymal arteries, such as the axillary, brachial, or iliac arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/4\">",
"     4",
"    </a>",
"    ]. Such peripheral artery aneurysms only occur among Kawasaki patients with giant coronary artery aneurysms. Peripheral arterial obstruction can lead to ischemia and gangrene; this complication generally accompanies other manifestations of severe disease such as giant CAAs and aneurysms in peripheral arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vasculitis of KD generally spares visceral vessels, so involvement of other organ systems is unusual. Nonetheless, any vascular bed may be affected. Case reports have included KD presenting as a cerebrovascular accident (eg, acute encephalopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/68\">",
"     68",
"    </a>",
"    ], stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/69\">",
"     69",
"    </a>",
"    ]), gastrointestinal obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/70\">",
"     70",
"    </a>",
"    ] or pseudo-obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/71\">",
"     71",
"    </a>",
"    ], or acute abdominal catastrophe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242699572\">",
"    <span class=\"h2\">",
"     Long-term complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329966460\">",
"    <span class=\"h3\">",
"     Risk for atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have regressed or persistent aneurysms are assumed to be an &ldquo;at risk&rdquo; population for early atherosclerotic disease. In these patients, the thresholds for treatment of risk factors for adult atherosclerotic heart disease are lower than in the general population (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"local\" href=\"#H13231815\">",
"     'Long-term follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As prospective evidence is still lacking, data to support this approach are indirect and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In long-term follow-up studies, intravascular ultrasound demonstrated thickened intima in patients at the site of coronary artery aneurysms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Histopathologic findings in patients who died after 15 years of age included intimal thickening, and thrombotic occlusion in four of six persistent aneurysms. In one 39 year old patient, there were advanced atherosclerotic changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ultrasound findings of carotid atherosclerosis were seen, independent of dyslipidemia, 6 to 20 years after KD was diagnosed among patients with coronary artery aneurysms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coronary angiographic findings of increased peripheral arterial stiffness and diminished vascular reactivity were reported in patients at 10 year follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who have persistent CAAs may have ongoing low-grade systemic inflammation, with higher levels of C-reactive protein (CRP) than patients with KD who never had aneurysms or normal controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are conflicting about the risk of early atherosclerosis in patients who never had any documented coronary artery abnormalities. Several studies report an increased risk for atherosclerosis in these patients based on indirect measures. These include studies showing endothelium-dependent abnormal brachial artery reactivity (indirect measure of potential atherosclerotic disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/77\">",
"     77",
"    </a>",
"    ], higher brachial-radial artery mean pulse wave Doppler velocity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/78,79\">",
"     78,79",
"    </a>",
"    ], and lower myocardial flow reserve and higher total coronary resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/80\">",
"     80",
"    </a>",
"    ]. Other studies have failed to show long-term abnormalities of peripheral vascular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/81\">",
"     81",
"    </a>",
"    ]. In addition, studies of coronary endothelial function in which acetylcholine was administered in the epicardial coronary arteries have shown conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329966476\">",
"    <span class=\"h3\">",
"     Myocardial function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because myocarditis is a nearly universal phenomenon in early KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/3,4,8,9\">",
"     3,4,8,9",
"    </a>",
"    ],",
"    <strong>",
"    </strong>",
"    some investigators have expressed concern about long-term myocardial sequelae even in the always-normal KD population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/84\">",
"     84",
"    </a>",
"    ]. However, prospectively gathered data are needed to verify whether this should be a long-term concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242696505\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following cardiac testing is performed in all patients diagnosed with KD to detect any cardiovascular sequelae and to monitor their course. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231738\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography should be performed as soon as the diagnosis of KD is suspected in order to establish a baseline for longitudinal follow-up. In addition, in a subset of patients with fever and incomplete criteria, findings on echocardiography are helpful in the decision of whether IVIG should be administered (",
"    <a class=\"graphic graphic_algorithm graphicRef79349 \" href=\"mobipreview.htm?22/0/22543\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11814?source=see_link&amp;anchor=H2509298#H2509298\">",
"     \"Incomplete (atypical) Kawasaki disease\", section on 'Criteria for treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography has a high sensitivity and specificity for detection proximal coronary arterial dilatation in the acute phase of illness and other noncoronary artery abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/85\">",
"     85",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    To obtain the best images, children under two years of age are usually sedated. After the baseline echocardiogram is obtained at diagnosis, echocardiography is usually repeated at approximately two and six weeks of illness. Importantly, in children at higher risk for CAAs (ie, because of abnormalities on baseline echocardiography or persistent or recrudescent fever), more frequent echocardiography is helpful in guiding appropriate therapy. Finally, for children with giant CAAs, we perform echocardiography for surveillance of thrombus formation at least twice weekly during the period of time that coronary arteries are enlarging, then once weekly in the high-risk period of the first 45 days of illness, monthly until the third month of disease, and then once every three months until the end of the first year after illness onset.",
"   </p>",
"   <p>",
"    Coronary arteries are traditionally classified as aneurysmal if they meet",
"    <strong>",
"     at least one",
"    </strong>",
"    <strong>",
"     of the following criteria",
"    </strong>",
"    set forth by the Japanese Ministry of Health criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Internal lumen diameter &gt;3 mm in children less than five years of age, or &gt;4 in children five years of age or greater",
"     </li>",
"     <li>",
"      Internal diameter of a segment at least 1.5 times the size of an adjacent segment",
"     </li>",
"     <li>",
"      The coronary lumen is clearly irregular.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the above criteria do not adjust for patient size, an important determinant of coronary dimension.",
"    <strong>",
"    </strong>",
"    As a result, coronary arteries are often expressed as standard deviations units or z scores, adjusted for body surface area (",
"    <a class=\"graphic graphic_figure graphicRef59238 \" href=\"mobipreview.htm?4/53/4959\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/87\">",
"     87",
"    </a>",
"    ]. Indeed, it is likely that the most accurate system of classifying aneurysms relies on z scores rather than using absolute measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/88\">",
"     88",
"    </a>",
"    ]. Interestingly, coronary dimensions in patients with KD at presentation are larger than normal. However, whether this is a reflection of the vasculitis or due to an associated factor such as fever is difficult to ascertain because there are no comparison z scores available for febrile children without KD.",
"   </p>",
"   <p>",
"    In a multicenter study in which echocardiograms were read in a central core laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/33\">",
"     33",
"    </a>",
"    ], the median z score at the time of presentation was 1.43, significantly higher than the expected population median of 0. For most patients, z scores decreased at one and five weeks following the baseline evaluation, although they were still increased compared to the normal afebrile population. In one in four patients, at least one echocardiogram in the five-week observation period included a proximal right coronary artery or left anterior descending coronary artery z score of 2.5; 5 percent had at",
"    <sup>",
"    </sup>",
"    least one z score &ge; 5. Coronary artery segments with z scores &lt;2.5 at initial evaluation usually do not usually dilate over the ensuing weeks. Perivascular brightness of the coronary artery walls, lack of tapering, and ectasia (coronary z scores 2.0 to 2.5) are thought to be soft signs of KD, although their predictive validity is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiography also detects other noncoronary artery abnormalities including depressed myocardial contractility, valvular lesions, and pericardial effusions. (See",
"    <a class=\"local\" href=\"#H242697570\">",
"     'Myocardial dysfunction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H242698055\">",
"     'Valvular regurgitation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H242698174\">",
"     'Pericardial effusion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231745\">",
"    <span class=\"h2\">",
"     Other noninvasive tests to image coronary artery anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although echocardiography has high sensitivity and specificity for detection of proximal coronary artery aneurysms in the early phases of KD in infants and young children, our impression is that it is less sensitive for detecting distal lesions and coronary artery stenosis which steadily worsen over time in coronary arterial segments affected by aneurysms. For this reason, ultrafast computed tomographic angiography (CTA) and magnetic resonance angiography (MRA) are used to obtain high-resolution coronary images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/89-93\">",
"     89-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both CTA and MRA imaging are optimized with a slow heart rate, and intravenous beta blockade may be necessary in young children to obtain the best images. Anesthesia is needed to perform both types of noninvasive angiography when children are unable to stay still. CTA exposes children to ionizing radiation. Although the radiation dosages are ever decreasing, this is still a risk in children who require repeated studies. However, the quality of coronary imaging is generally superior to that of cardiac MRA. Nonetheless, MRA has several advantages over ultrafast CTA, because it can be combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    - or adenosine-stress testing, and can also delineate the territory affected by myocardial infarction using delayed enhancement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242698454\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) may show arrhythmia, slight prolongation of the PR and QT intervals, or nonspecific ST and T wave changes. In patients with aneurysms, myocardial infarction can by indicated by ECG abnormalities, supported by elevation in biochemical markers of myocardial necrosis (eg, troponin, CK-MB) and myocardial imaging studies showing new loss of viable myocardium or new regional wall motion abnormality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231752\">",
"    <span class=\"h2\">",
"     Stress testing for inducible ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with aneurysms are advised to undergo periodic testing for inducible ischemia in order to detect and, if present, to quantify the degree of coronary insufficiency. Only small case series have reported the results of stress testing in children with KD and aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/94-104\">",
"     94-104",
"    </a>",
"    ]. Thus, the choice of testing technique is based upon the larger adult literature, the ability of a child to cooperate, potential risks (such as radiation exposure or anesthesia), and the institutional experience. Because the risk of false positive testing is highest when the probability of disease is low, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend stress testing in patients without a history of aneurysms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In determining the most appropriate stress test to detect ischemia in children with coronary artery aneurysms, the following should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise stress testing is preferred to pharmacologic stress testing because it is more physiologic. However, if children are unable to cooperate with the exercise protocol, pharmacological stress testing using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      MRA avoids radiation exposure and can assess both perfusion and wall motion abnormalities. This testing is usually done under anesthesia. Pediatric experience with pharmacologic stress testing using positron emission tomography (PET) is limited.",
"     </li>",
"     <li>",
"      Exercise testing for inducible ischemia with only electrocardiographic monitoring for ischemic changes has a relatively low mean sensitivity and specificity in adult series.",
"     </li>",
"     <li>",
"      The predictive value of exercise stress testing is enhanced with the use of non-invasive imaging. In weighing the relative merits of imaging techniques, stress echocardiography compared with SPECT perfusion imaging has a higher success rate, greater specificity, and avoids radiation exposure and the need for placement of an intravenous line; the latter is a major advantage for younger children. However, stress echocardiography is dependent upon acoustic windows, and, compared to SPECT imaging, has greater interobserver variability and lower sensitivity. For patients with KD with left main or multi-vessel disease leading to &ldquo;balanced ischemia,&rdquo; SPECT imaging may be less sensitive than stress echocardiography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231759\">",
"    <span class=\"h2\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective coronary angiography has historically been the &ldquo;gold standard&rdquo; for evaluation of coronary architecture in children with KD. In fact, serial angiography in Japanese patients has defined the natural history of the disease. Coronary angiography offers detailed definition of the coronary lumen anatomy and blood flow characteristics, including collateral flow. It can detect and quantify stenosis, obstruction, and aneurysms of the coronary arteries and the collateral circulation (",
"    <a class=\"graphic graphic_movie graphicRef65317 \" href=\"mobipreview.htm?35/29/36318\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef53864 \" href=\"mobipreview.htm?18/43/19134\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef76878 \" href=\"mobipreview.htm?16/54/17262\">",
"     movie 3",
"    </a>",
"    ). Intraluminal ultrasound performed at the time of cardiac catheterization can add information about the structure of the coronary arterial wall, and measurements of coronary flow reserve with adenosine stress may also be useful. Intravenous or intracoronary infusion of vasoactive drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    , acetylcholine, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"     ergotamine",
"    </a>",
"    with computer-based vascular edge detection and quantitative measurement can provide information on vascular function.",
"   </p>",
"   <p>",
"    Because cardiac catheterization with angiography has a greater risk than noninvasive methods and exposes children to ionizing radiation, its use should be restricted to patients with significant coronary artery aneurysms in whom:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninvasive testing cannot provide equivalent imaging without greater risk.",
"     </li>",
"     <li>",
"      Symptoms or noninvasive evidence of ischemia suggest that coronary revascularization may be indicated. (See",
"      <a class=\"local\" href=\"#H13231794\">",
"       'Coronary revascularization procedures'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Angiographic imaging is otherwise needed to guide therapy including the choice of optimal anti-thrombotic therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      versus only anti-platelet therapy). (See",
"      <a class=\"local\" href=\"#H13231787\">",
"       'Myocardial infarction and coronary thrombosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some clinicians perform routine cardiac catheterization to assess status after surgical revascularization or percutaneous coronary intervention. Because aneurysms in KD may evolve and regress over time, we generally recommend cardiac catheterization or coronary CTA in patients with large or complex aneurysms approximately 12 months after illness onset. Cardiac catheterization is performed earlier if there are clinical or noninvasive induced signs of ischemia.",
"   </p>",
"   <p>",
"    When cardiac catheterization is first performed, subclavian arteriograms should be performed to delineate the anatomy of the internal mammary arteries and to exclude brachial artery aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/55\">",
"     55",
"    </a>",
"    ]. Similarly, abdominal aortography is useful to image arteries arising from the descending aorta, including the iliac and femoral arteries to detect any abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242698963\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of cardiovascular sequelae of KD includes prevention of coronary thrombosis, treatment of patients with myocardial infarction and coronary thrombosis, and in some severe rare cases, cardiac transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231780\">",
"    <span class=\"h2\">",
"     Prevention of coronary thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that contribute to the development of coronary arterial thrombosis during the first weeks of KD are activation of platelets and of the endothelium and formation of CAAs, which results in stagnant blood flow. To reduce the risk of coronary arterial thrombosis, all patients with KD are treated with low-dose (antiplatelet)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    until it is clear that aneurysms will not develop (after one month) or unless there are contraindications to its use.",
"   </p>",
"   <p>",
"    The anti-thrombotic regimen for patients with persistent CAAs is based upon adult data for secondary prevention of coronary artery disease, as well as first principles, because there are no available data from randomized trials of anti-thrombotic therapy in children with KD and CAAs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) remains the cornerstone of anti-thrombotic therapy in patients with KD and CAAs. Although annual influenza vaccination is recommended for all children, it is especially imperative to vaccinate patients with KD on chronic aspirin therapy because of the association of aspirin therapy and influenza with Reye syndrome. Other antiplatelet agents (eg, thienopyridines [",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ]) should be temporarily substituted for aspirin during episodes of influenza or chicken pox. Finally, long-term therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      should be avoided because it antagonizes aspirin-induced platelet inhibition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depending upon the size of the aneurysm and age of the patient, other anticoagulation and antiplatelet therapy may be added.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with small CAAs are generally managed with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      alone.",
"     </li>",
"     <li>",
"      Those with moderate to large CAAs can be managed with low-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , and in some cases, inhibitors of ADP-induced platelet aggregation (eg, thienopyridines such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) may be added. In the absence of any evidence-based data, the decision to add thienopyridines to aspirin is often made on a case-by-case basis. However, we tend to use dual anti-platelet therapy in patients whose aneurysms are just below the threshold for institution of anticoagulation (ie, aneurysms with maximum internal diameter between 5 and 7 mm, or have z scores between +7 and +9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with giant CAAs (ie, maximum internal diameter of &ge; 8 mm or z score &ge; +10), a lower rate of myocardial infarction has been noted when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/106\">",
"       106",
"      </a>",
"      ]. In general, the goal of therapy is for an INR between 2.0 and 3.0, although the worst aneurysms may be managed with an anti-thrombotic regimen of aspirin and warfarin similar to that for prosthetic mitral valves with an INR goal between 2.5 and 3.5.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Especially in young infants, a z score of &ge; +10 rather than maximum internal diameter of &ge; 8 mm should be used as the criterion for use of anticoagulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/88\">",
"       88",
"      </a>",
"      ]. In infants, or in the older child in whom",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is difficult to regulate, low-molecular-weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (LMWH) is often used instead of warfarin. In one study patients with giant CAAs (defined as a z score &ge; +10), there was no difference in the frequency of thrombotic coronary artery occlusions between LMWH and warfarin therapy. Severe bleeding was more frequently observed in patients treated with warfarin but minor bleeding was more frequent in patients treated with LMWH. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14986?source=see_link&amp;anchor=H4#H4\">",
"       \"Management of thrombosis in the newborn\", section on 'Anticoagulant therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In rare circumstances, for example in young infants with giant CAAs who have had coronary thrombosis treated with thrombolysis, triple therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , a thienopyridine, and anticoagulation (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or LMWH) is sometimes used for a limited period of time. In such instances, the risks of bleeding must be balanced against the risks of coronary thrombosis and occlusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with CAAs should have reproductive counseling during adolescence and, once pregnant, should follow anticoagulation guidelines similar to those of the obstetric patient with a prosthetic heart valve. Outcomes of pregnancy in women with CAAs in a small series appear to be excellent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/107\">",
"       107",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1882?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of pregnant women with prosthetic heart valves\", section on 'Anticoagulation during pregnancy for women with mechanical heart valves'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231787\">",
"    <span class=\"h2\">",
"     Myocardial infarction and coronary thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction is the principal cause of KD mortality and occurs most frequently among patients with giant CAAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/17\">",
"     17",
"    </a>",
"    ]. Although the relative risk of myocardial infarction is highest in the first six to 12 months of the disease and declines after the two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], risk continues into adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/18,19,108\">",
"     18,19,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because myocardial infarction is rare in KD subjects, principles of treatment are derived from those used in the adult population with atherosclerotic coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who present with acute thrombotic occlusion of a coronary artery and who are large enough for use of adult-sized catheters, immediate angiography with mechanical restoration of myocardial blood flow is the procedure of choice.",
"     </li>",
"     <li>",
"      For younger children, combination therapy is administered with systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (recombinant tissue-type plasminogen [tPA], dosing at 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour intravenously for six hours), and low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (initial dosing at 10",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour, which is adjusted to a targeted aPTT between 50 and 70 seconds). Echocardiographic imaging then is performed to reassess the thrombus, and alteplase may be continued for longer if the thrombus has not resolved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is a lack of supportive data, we have treated coronary thrombosis in children with KD as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For some patients with a particularly large thrombus burden,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      is intravenously administered at half dosing (0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour), together with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      (platelet glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIA",
"      </span>",
"      inhibitor, as an initial bolus of 0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      bolus over 30 minutes, followed by an infusion of 0.125",
"      <span class=\"nowrap\">",
"       micrograms/kg",
"      </span>",
"      per minute for 12 hours).",
"     </li>",
"     <li>",
"      When echocardiographic surveillance during the acute or subacute phase of disease reveals a new mural, nonocclusive thrombus,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      together is administered with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour) to prevent clot extension. &nbsp;",
"     </li>",
"     <li>",
"      Following acute myocardial infarction, we may treat patients with beta blockers, angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers, (ARBs), and aldosterone blockers in addition to their anti-thrombotic regimen, in accordance with standard post-myocardial infarction therapy in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/59/7098?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of the non-acute management of ST elevation myocardial infarction\", section on 'Further medical therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term outcome in patients with KD after myocardial infarction is highly related to ejection fraction, with 30-year survival after myocardial infarction being poor for patients with ejection fraction &le;45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231794\">",
"    <span class=\"h2\">",
"     Coronary revascularization procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery revascularization, either by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) procedure, is performed to relieve symptoms of angina and to reduce the risk of myocardial infarction or sudden death in patients with evidence of reversible ischemia on stress testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/20\">",
"     20",
"    </a>",
"    ]. The decision to perform a coronary revascularization procedure in a patient with KD is based on consensus of experts, clinical experience in adults with atherosclerotic coronary artery disease, and retrospective reviews in patients with KD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/109-112\">",
"     109-112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized clinical trials assessing the relative merits of PCI versus CABG procedure in KD. A recent retrospective Japanese survey suggested that patients who undergo PCI as a first revascularization procedure, compared to those whose first procedure is surgical, had similar rates of mortality and acute myocardial infarction. However, the PCI group was more likely to undergo repeat revascularization procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/113\">",
"     113",
"    </a>",
"    ]. The re-interventions rate was especially high in patients whose CABG procedures were performed in the absence of ischemic findings, presumably because competitive flow caused graft failure.",
"   </p>",
"   <p>",
"    The Research Committee of the Japanese Ministry of Health, Labor and Welfare recommends PCI for patients with the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/114\">",
"     114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemic symptoms",
"     </li>",
"     <li>",
"      Reversible ischemia on stress testing",
"     </li>",
"     <li>",
"      75 percent stenosis of the left anterior descending coronary artery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Performance of PCI in the child or adolescent after KD should be performed by an adult interventional cardiologist, relying on support from pediatric specialists in smaller children. Interventional catheterization procedures used in patients with KD are similar to those in adults. However, because affected vessels become calcified, rotational ablation and stent placement are generally preferred to percutaneous transluminal coronary angioplasty after a few years have passed since disease onset.",
"   </p>",
"   <p>",
"    The above Japanese committee recommends CABG procedure rather than PCI for patients with the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/114\">",
"     114",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe left ventricular dysfunction",
"     </li>",
"     <li>",
"      Coronary lesions with multiple, ostial, or long-segment coronary artery stenoses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical revascularization is most often performed in children who either have symptoms of angina, or who have clinically relevant obstruction in two or more major coronary arteries or in the left main coronary artery, and thus are considered to be at high risk of myocardial infarction. CABG procedures are only performed when the myocardium to be supplied is viable and the artery beyond the planned graft site is not stenotic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/115\">",
"     115",
"    </a>",
"    ]. In the current era, almost all grafts are derived from systemic arteries (ie, internal mammary or radial artery) rather than saphenous veins, because these are able to grow in size as the child matures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. Grafts have better long-term patency when performed in the older child, but subsequent use of PCI can extend graft longevity and children as young as one year of age have undergone surgical revascularization. In a recent single-center experience, 25-year survival after CABG procedure was 95 percent, but only 60 percent of patients had escaped reoperation or PCI by this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231801\">",
"    <span class=\"h2\">",
"     Cardiac transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac transplantation is reserved for patients with end-stage ischemic cardiomyopathy who are not candidates for coronary revascularization procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13231815\">",
"    <span class=\"h1\">",
"     LONG-TERM FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, we generally use the 2004 American Heart Association recommendations for long-term follow-up, with the exception that noninvasive methods of coronary imaging, such as CTA and MRA, may supplant diagnostic cardiac catheterization, and young patients with coronary z scores of &ge; +10 are often treated in accordance with recommendations for giant coronary aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/2\">",
"     2",
"    </a>",
"    ]. These guidelines base the frequency of follow-up including testing, use of medications (eg, anticoagulation), and exercise restrictions on the coronary artery status of the patient (",
"    <a class=\"graphic graphic_table graphicRef62986 \" href=\"mobipreview.htm?43/25/44444\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All patients with KD and their families should be counseled for risk factors for atherosclerotic coronary disease, regardless of severity of coronary disease in the acute phase of their illness. All patients older than two years of age are also screened for dyslipidemia by either a fasting lipid profile, or lipid profile with directly measured LDL cholesterol one year after the acute phase of their disease. If the results are normal, repeat lipid screening is performed every five years. We stress the importance of a heart healthy diet, regular exercise, and avoidance of smoking including passive smoking. Thresholds for treatment of risk factors (eg, hyperlipidemia, hypertension), which are lower than the normal pediatric population, have been proposed in accordance with severity of coronary involvement (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"mobipreview.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ). As patients with persistent aneurysms approach adulthood, we believe that they should be treated according to adult guidelines for secondary prevention for cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=see_link&amp;anchor=H235228239#H235228239\">",
"     \"Definition and screening for dyslipidemia in children\", section on 'Lipid screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25352?source=see_link\">",
"     \"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who never had CAAs, the optimal frequency and intensity of follow-up is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/84,117\">",
"     84,117",
"    </a>",
"    ]. Because the risk conferred by KD will not be known until the earliest Japanese cohorts reach middle-age adulthood, we prefer to see such patients at five-year intervals for preventive cardiology counseling and echocardiographic assessment. With continued surveillance, the long-term repercussions of KD, including its effects on risks of coronary artery, valvular, and myocardial disease, will be more fully elucidated, and will inform clinicians on how best to manage these patients long-term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329969197\">",
"    <span class=\"h2\">",
"     Participation in competitive sports",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise recommendations in patients with a history of KD are tailored to the degree of coronary involvement. All patients with KD should avoid a sedentary lifestyle, and counseling should proactively address the importance of regular aerobic exercise.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients without coronary abnormalities at any stage of the disease, and those with transient coronary artery ectasia can resume participation in all competitive sports after symptoms have resolved, generally at about six weeks after illness onset.",
"     </li>",
"     <li>",
"      In patients with aneurysms, exercise recommendations are guided by findings on stress testing with myocardial perfusion imaging and evaluation of left ventricular function. In general, we follow the 36th Bethesda Conference recommendations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/6/30826/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with isolated small- to medium-sized aneurysms who have normal left ventricular function and absence of exercise-induced ischemia or arrhythmia can participate in low to moderate static and dynamic competitive sports (Classes IA, IB, IIA, and IIB) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"mobipreview.htm?28/51/29489\">",
"       figure 2",
"      </a>",
"      ).",
"      <strong>",
"      </strong>",
"      Stress testing with evaluation of myocardial perfusion in this population is generally repeated at one- to two-year intervals.",
"     </li>",
"     <li>",
"      Among patients with one or more large or giant CAAs, multiple (segmented) aneurysms, or complex aneurysms with or without obstruction, participation in Class IA and IIA sports are permitted when stress testing and myocardial function are normal. Because this subset of patients is at higher risk, stress testing is repeated annually or with symptoms (eg, chest pain or dyspnea with exertion).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have had a recent myocardial infarction or revascularization procedure are restricted from competitive sports until their recovery is complete, at which time exercise and myocardial function are reevaluated. If left ventricular ejection fraction is normal and exercise testing reveals no reversible ischemia or arrhythmia, participation in Class IA and IB sports is permitted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, however, patients treated with a combination of anticoagulation and anti-platelet drugs, or with dual anti-platelet therapy should avoid competitive sports that entail a danger of high-speed collision because of the risk of a severe bleeding adverse event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/8/3201?source=see_link\">",
"       \"Patient information: Kawasaki disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242699421\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular complications are the major cause of mortality and morbidity in patients with KD (KD). &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major complication of KD is coronary artery aneurysms (CAAs). Patients also can develop decreased myocardial contractility in the acute phase, valvular regurgitation, pericardial effusion, and peripheral artery aneurysms. Myocardial infarction and ischemia, the two most serious sequelae, only develop in patients with coronary disease. (See",
"      <a class=\"local\" href=\"#H242696497\">",
"       'Cardiovascular complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The highest risk of morbidity and mortality are associated with giant CAAs (internal diameter &gt;8 mm or z score &ge; +10). Up to one-third of such aneurysms become obstructed, and are associated with myocardial infarction, arrhythmias, or sudden death. Risk factors associated with CAAs include late diagnosis and treatment with intravenous gamma globulin (IVIG), age &lt;1 year and &gt;9 years, male gender, prolonged fever, failure to respond to initial IVIG therapy, and laboratory findings suggestive of persistent and severe inflammation. (See",
"      <a class=\"local\" href=\"#H242696532\">",
"       'Coronary artery aneurysm'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Typically, aneurysms increase over the first four to six weeks after illness onset, and approximately 50 percent will regress to normal lumen diameter over the next two years. The likelihood that an aneurysm will regress to normal lumen diameter is most strongly related to its maximum diameter; giant aneurysms are least likely to regress. (See",
"      <a class=\"local\" href=\"#H242698581\">",
"       'Natural course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have regressed or persistent aneurysms are assumed to be an &ldquo;at risk&rdquo; population for early atherosclerotic disease, however, it remains unknown whether patients without coronary involvement are at increased risk for atherosclerosis. (See",
"      <a class=\"local\" href=\"#H329966460\">",
"       'Risk for atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all patients with KD, cardiac testing includes echocardiography (eg, detection of CAAs and other cardiac abnormalities), electrocardiography, and stress testing (eg, detection of inducible ischemia). Patients with coronary aneurysms should undergo stress testing with myocardial perfusion imaging to detect to inducible ischemia. Computed tomographic angiography (CTA) or magnetic resonance angiography (MRA) is performed if imaging by echocardiography is inadequate to image the coronary arteries in patients without known aneurysms. CTA, MRA, or cardiac catheterization is used to fully delineate the coronary arterial anatomy in patients with known aneurysms. (See",
"      <a class=\"local\" href=\"#H242696505\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of cardiovascular sequelae of KD includes prevention of coronary thrombosis, treatment of patients with myocardial infarction and coronary thrombosis, and in some severe rare cases, cardiac transplantation. (See",
"      <a class=\"local\" href=\"#H242698963\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend all patients with KD and persistent CAAs receive antithrombotic therapy to prevent coronary thrombosis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We tailor our therapy based on the size of the CAAs. In our practice, all patients receive low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy. Other antiplatelet agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) may be added to the drug regimen of patients with moderate to large CAAs. Patients with giant CAAs should be treated with aspirin together with anticoagulation (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or low-molecular-weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13231780\">",
"       'Prevention of coronary thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who suffer a myocardial infarction, we recommend emergent therapy for reperfusion and revascularization (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The therapeutic intervention is dependent on the size of the patient. In patients large enough for use of adult-size catheters, we recommend immediate angiography and mechanical restoration of blood flow (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In smaller patients, systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (recombinant tissue-type plasminogen [tPA]) at a rate of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg/hour",
"      </span>",
"      IV for six hours, is administered together with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13231787\">",
"       'Myocardial infarction and coronary thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with clinical signs of coronary ischemia including reversible ischemia with exertion, we suggest that coronary artery revascularization intervention be performed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13231794\">",
"       'Coronary revascularization procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In our practice, the long-term follow-up care of patients with KD is generally consistent with the published recommendations of the American Heart Association (",
"      <a class=\"graphic graphic_table graphicRef62986 \" href=\"mobipreview.htm?43/25/44444\">",
"       table 1",
"      </a>",
"      ). These guidelines are based on the coronary artery status of the patient, and outline the frequency of follow-up visits and include testing, the use of medications including anticoagulation, and exercise restriction. Counseling regarding risk factors for atherosclerosis and healthy heart diet is provided, and screening for dyslipidemia is performed in all children with KD. In addition, exercise recommendations are given to patients and their families based on the coronary artery status of the patient. (See",
"      <a class=\"local\" href=\"#H13231815\">",
"       'Long-term follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13235158\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Masato Takahashi, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/1\">",
"      Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi 1967; 16:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/2\">",
"      Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/3\">",
"      Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978; 61:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/4\">",
"      Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn 1991; 41:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/5\">",
"      Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 2003; 112:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/6\">",
"      Chang RK. Hospitalizations for Kawasaki disease among children in the United States, 1988-1997. Pediatrics 2002; 109:e87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/7\">",
"      Takahashi K, Oharaseki T, Naoe S, et al. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int 2005; 47:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/8\">",
"      Yutani C, Okano K, Kamiya T, et al. Histopathological study on right endomyocardial biopsy of Kawasaki disease. Br Heart J 1980; 43:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/9\">",
"      Yutani C, Go S, Kamiya T, et al. Cardiac biopsy of Kawasaki disease. Arch Pathol Lab Med 1981; 105:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/10\">",
"      Burns JC. Kawasaki Disease update. Indian J Pediatr 2009; 76:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/11\">",
"      Suzuki A, Miyagawa-Tomita S, Komatsu K, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study. Circulation 2000; 101:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/12\">",
"      Chen Y, Shang S, Zhang C, et al. Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis. Pediatr Hematol Oncol 2010; 27:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/13\">",
"      Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J 2003; 22:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/14\">",
"      Simonini G, Pagnini I, Innocenti L, et al. Macrophage activation syndrome/Hemophagocytic Lymphohistiocytosis and Kawasaki disease. Pediatr Blood Cancer 2010; 55:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/15\">",
"      Titze U, Janka G, Schneider EM, et al. Hemophagocytic lymphohistiocytosis and Kawasaki disease: combined manifestation and differential diagnosis. Pediatr Blood Cancer 2009; 53:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/16\">",
"      Kahn AM, Budoff MJ, Daniels LB, et al. Calcium scoring in patients with a history of Kawasaki disease. JACC Cardiovasc Imaging 2012; 5:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/17\">",
"      Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986; 108:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/18\">",
"      Tsuda E, Hirata T, Matsuo O, et al. The 30-year outcome for patients after myocardial infarction due to coronary artery lesions caused by Kawasaki disease. Pediatr Cardiol 2011; 32:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/19\">",
"      Burns JC, Shike H, Gordon JB, et al. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996; 28:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/20\">",
"      Suda K, Iemura M, Nishiono H, et al. Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms: a single-institution experience. Circulation 2011; 123:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/21\">",
"      Baer AZ, Rubin LG, Shapiro CA, et al. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome. Arch Pediatr Adolesc Med 2006; 160:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/22\">",
"      Kitamura S, Kameda Y, Seki T, et al. Long-term outcome of myocardial revascularization in patients with Kawasaki coronary artery disease. A multicenter cooperative study. J Thorac Cardiovasc Surg 1994; 107:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/23\">",
"      Burns JC, Glod&eacute; MP. Kawasaki syndrome. Lancet 2004; 364:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/24\">",
"      Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/25\">",
"      McNeal-Davidson A, Fournier A, Scuccimarri R, et al. The fate and observed management of giant coronary artery aneurysms secondary to Kawasaki disease in the Province of Quebec: the complete series since 1976. Pediatr Cardiol 2013; 34:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/26\">",
"      Minich LL, Sleeper LA, Atz AM, et al. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics 2007; 120:e1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/27\">",
"      Muta H, Ishii M, Sakaue T, et al. Older age is a risk factor for the development of cardiovascular sequelae in Kawasaki disease. Pediatrics 2004; 114:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/28\">",
"      Song D, Yeo Y, Ha K, et al. Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr 2009; 168:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/29\">",
"      Kim T, Choi W, Woo CW, et al. Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr 2007; 166:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/30\">",
"      Beiser AS, Takahashi M, Baker AL, et al. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998; 81:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/31\">",
"      Sabharwal T, Manlhiot C, Benseler SM, et al. Comparison of factors associated with coronary artery dilation only versus coronary artery aneurysms in patients with Kawasaki disease. Am J Cardiol 2009; 104:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/32\">",
"      Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/33\">",
"      McCrindle BW, Li JS, Minich LL, et al. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation 2007; 116:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/34\">",
"      Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/35\">",
"      Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004; 46:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/36\">",
"      Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986; 108:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/37\">",
"      Belay ED, Maddox RA, Holman RC, et al. Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003. Pediatr Infect Dis J 2006; 25:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/38\">",
"      Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr 2000; 137:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/39\">",
"      Momenah T, Sanatani S, Potts J, et al. Kawasaki disease in the older child. Pediatrics 1998; 102:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/40\">",
"      Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/41\">",
"      Manlhiot C, Yeung RS, Clarizia NA, et al. Kawasaki disease at the extremes of the age spectrum. Pediatrics 2009; 124:e410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/42\">",
"      Yeo Y, Kim T, Ha K, et al. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr 2009; 168:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/43\">",
"      Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/44\">",
"      Shimizu C, Matsubara T, Onouchi Y, et al. Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. J Hum Genet 2010; 55:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/45\">",
"      Kariyazono H, Ohno T, Khajoee V, et al. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 2004; 56:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/46\">",
"      Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987; 75:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/47\">",
"      Fujiwara T, Fujiwara H, Hamashima Y. Size of coronary aneurysm as a determinant factor of the prognosis in Kawasaki disease: clinicopathologic study of coronary aneurysms. Prog Clin Biol Res 1987; 250:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/48\">",
"      Nakano H, Ueda K, Saito A, Nojima K. Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease. Am J Cardiol 1985; 56:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/49\">",
"      Sugimura T, Kato H, Inoue O, et al. Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 1994; 89:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/50\">",
"      Tsuda E, Kamiya T, Kimura K, et al. Coronary artery dilatation exceeding 4.0 mm during acute Kawasaki disease predicts a high probability of subsequent late intima-medial thickening. Pediatr Cardiol 2002; 23:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/51\">",
"      Iemura M, Ishii M, Sugimura T, et al. Long term consequences of regressed coronary aneurysms after Kawasaki disease: vascular wall morphology and function. Heart 2000; 83:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/52\">",
"      Kurisu Y, Azumi T, Sugahara T, et al. Variation in coronary arterial dimension (distensible abnormality) after disappearing aneurysm in Kawasaki disease. Am Heart J 1987; 114:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/53\">",
"      Matsumura K, Okuda Y, Ito T, et al. Coronary angiography of Kawasaki disease with the coronary vasodilator dipyridamole: assessment of distensibility of affected coronary arterial wall. Angiology 1988; 39:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/54\">",
"      Sugimura T, Kato H, Inoue O, et al. Vasodilatory response of the coronary arteries after Kawasaki disease: evaluation by intracoronary injection of isosorbide dinitrate. J Pediatr 1992; 121:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/55\">",
"      Suzuki A, Kamiya T, Kuwahara N, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 1986; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     Kamiya, T, Suzuki, et al. Angiographic follow-up study of coronary artery lesion in the cases with a history of Kawasaki disease - with a focus on the follow-up more than ten years after the onset of the disease. In: Kawasaki Disease. Proceedings of the 5th International Kawasaki Disease Symposium, Kato, H (Eds), Elsevier Science B.V., Amsterdam 1995. p.569.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/57\">",
"      Tsuda E, Kamiya T, Ono Y, et al. Incidence of stenotic lesions predicted by acute phase changes in coronary arterial diameter during Kawasaki disease. Pediatr Cardiol 2005; 26:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/58\">",
"      Printz BF, Sleeper LA, Newburger JW, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol 2011; 57:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/59\">",
"      Moran AM, Newburger JW, Sanders SP, et al. Abnormal myocardial mechanics in Kawasaki disease: rapid response to gamma-globulin. Am Heart J 2000; 139:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/60\">",
"      Selamet Tierney ES, Newburger JW, Graham D, et al. Diastolic function in children with Kawasaki disease. Int J Cardiol 2011; 148:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/61\">",
"      Newburger JW, Sanders SP, Burns JC, et al. Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin. Circulation 1989; 79:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/62\">",
"      Ravekes WJ, Colan SD, Gauvreau K, et al. Aortic root dilation in Kawasaki disease. Am J Cardiol 2001; 87:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/63\">",
"      Ozdogu H, Boga C. Fatal cardiac tamponade in a patient with Kawasaki disease. Heart Lung 2005; 34:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/64\">",
"      Kuppuswamy M, Gukop P, Sutherland G, Venkatachalam C. Kawasaki disease presenting as cardiac tamponade with ruptured giant aneurysm of the right coronary artery. Interact Cardiovasc Thorac Surg 2010; 10:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/65\">",
"      Imai Y, Sunagawa K, Ayusawa M, et al. A fatal case of ruptured giant coronary artery aneurysm. Eur J Pediatr 2006; 165:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/66\">",
"      Maresi E, Passantino R, Midulla R, et al. Sudden infant death caused by a ruptured coronary aneurysm during acute phase of atypical Kawasaki disease. Hum Pathol 2001; 32:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/67\">",
"      Tomita S, Chung K, Mas M, et al. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis 1992; 14:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/68\">",
"      Tabarki B, Mahdhaoui A, Selmi H, et al. Kawasaki disease with predominant central nervous system involvement. Pediatr Neurol 2001; 25:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/69\">",
"      Suda K, Matsumura M, Ohta S. Kawasaki disease complicated by cerebral infarction. Cardiol Young 2003; 13:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/70\">",
"      Mele T, Evans M. Intestinal obstruction as a complication of Kawasaki disease. J Pediatr Surg 1996; 31:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/71\">",
"      Akikusa JD, Laxer RM, Friedman JN. Intestinal pseudoobstruction in Kawasaki disease. Pediatrics 2004; 113:e504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/72\">",
"      Zulian F, Falcini F, Zancan L, et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr 2003; 142:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/73\">",
"      Takahashi K, Oharaseki T, Naoe S. Pathological study of postcoronary arteritis in adolescents and young adults: with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol 2001; 22:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/74\">",
"      Noto N, Okada T, Yamasuge M, et al. Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics 2001; 107:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/75\">",
"      Cheung YF, Ho MH, Tam SC, Yung TC. Increased high sensitivity C reactive protein concentrations and increased arterial stiffness in children with a history of Kawasaki disease. Heart 2004; 90:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/76\">",
"      Mitani Y, Sawada H, Hayakawa H, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005; 111:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/77\">",
"      Dhillon R, Clarkson P, Donald AE, et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996; 94:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/78\">",
"      Cheung YF, Yung TC, Tam SC, et al. Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J Am Coll Cardiol 2004; 43:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/79\">",
"      Ooyanagi R, Fuse S, Tomita H, et al. Pulse wave velocity and ankle brachial index in patients with Kawasaki disease. Pediatr Int 2004; 46:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/80\">",
"      Muzik O, Paridon SM, Singh TP, et al. Quantification of myocardial blood flow and flow reserve in children with a history of Kawasaki disease and normal coronary arteries using positron emission tomography. J Am Coll Cardiol 1996; 28:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/81\">",
"      McCrindle BW, McIntyre S, Kim C, et al. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis? J Pediatr 2007; 151:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/82\">",
"      Mitani Y, Okuda Y, Shimpo H, et al. Impaired endothelial function in epicardial coronary arteries after Kawasaki disease. Circulation 1997; 96:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/83\">",
"      Yamakawa R, Ishii M, Sugimura T, et al. Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol 1998; 31:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/84\">",
"      Gordon JB, Kahn AM, Burns JC. When children with kawasaki disease grow up myocardial and vascular complications in adulthood. J Am Coll Cardiol 2009; 54:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/85\">",
"      Capannari TE, Daniels SR, Meyer RA, et al. Sensitivity, specificity and predictive value of two-dimensional echocardiography in detecting coronary artery aneurysms in patients with Kawasaki disease. J Am Coll Cardiol 1986; 7:355.",
"     </a>",
"    </li>",
"    <li>",
"     Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. 1984. Tokyo, Japan, Ministry of Health and Welfare.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/87\">",
"      de Zorzi A, Colan SD, Gauvreau K, et al. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998; 133:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/88\">",
"      Manlhiot C, Millar K, Golding F, McCrindle BW. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol 2010; 31:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/89\">",
"      Greil GF, Stuber M, Botnar RM, et al. Coronary magnetic resonance angiography in adolescents and young adults with kawasaki disease. Circulation 2002; 105:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/90\">",
"      Danias PG, Stuber M, Botnar RM, et al. Coronary MR angiography clinical applications and potential for imaging coronary artery disease. Magn Reson Imaging Clin N Am 2003; 11:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/91\">",
"      Mavrogeni S, Papadopoulos G, Douskou M, et al. Magnetic resonance angiography is equivalent to X-ray coronary angiography for the evaluation of coronary arteries in Kawasaki disease. J Am Coll Cardiol 2004; 43:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/92\">",
"      Sohn S, Kim HS, Lee SW. Multidetector row computed tomography for follow-up of patients with coronary artery aneurysms due to Kawasaki disease. Pediatr Cardiol 2004; 25:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/93\">",
"      Schmidt WA. Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 2004; 6:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/94\">",
"      Kondo C, Hiroe M, Nakanishi T, Takao A. Detection of coronary artery stenosis in children with Kawasaki disease. Usefulness of pharmacologic stress 201Tl myocardial tomography. Circulation 1989; 80:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/95\">",
"      Jan SL, Hwang B, Fu YC, et al. Comparison of 201Tl SPET and treadmill exercise testing in patients with Kawasaki disease. Nucl Med Commun 2000; 21:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/96\">",
"      Pahl E, Sehgal R, Chrystof D, et al. Feasibility of exercise stress echocardiography for the follow-up of children with coronary involvement secondary to Kawasaki disease. Circulation 1995; 91:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/97\">",
"      Henein MY, Dinarevic S, O'Sullivan CA, et al. Exercise echocardiography in children with Kawasaki disease: ventricular long axis is selectively abnormal. Am J Cardiol 1998; 81:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/98\">",
"      Noto N, Ayusawa M, Karasawa K, et al. Dobutamine stress echocardiography for detection of coronary artery stenosis in children with Kawasaki disease. J Am Coll Cardiol 1996; 27:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/99\">",
"      Kimball TR, Witt SA, Daniels SR. Dobutamine stress echocardiography in the assessment of suspected myocardial ischemia in children and young adults. Am J Cardiol 1997; 79:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/100\">",
"      Bezold LI, Lewin MB, Vick GW 3rd, Pignatelli R. Update on new technologies in pediatric echocardiography. Tex Heart Inst J 1997; 24:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/101\">",
"      M&uuml;hling O, Jerosch-Herold M, N&auml;bauer M, Wilke N. Assessment of ischemic heart disease using magnetic resonance first-pass perfusion imaging. Herz 2003; 28:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/102\">",
"      Kaul S, Ito H. Microvasculature in acute myocardial ischemia: part I: evolving concepts in pathophysiology, diagnosis, and treatment. Circulation 2004; 109:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/103\">",
"      Zilberman MV, Witt SA, Kimball TR. Is there a role for intravenous transpulmonary contrast imaging in pediatric stress echocardiography? J Am Soc Echocardiogr 2003; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/104\">",
"      Ishii M, Himeno W, Sawa M, et al. Assessment of the ability of myocardial contrast echocardiography with harmonic power Doppler imaging to identify perfusion abnormalities in patients with Kawasaki disease at rest and during dipyridamole stress. Pediatr Cardiol 2002; 23:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/105\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/106\">",
"      Sugahara Y, Ishii M, Muta H, et al. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol 2008; 29:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/107\">",
"      Tsuda E, Ishihara Y, Kawamata K, et al. Pregnancy and delivery in patients with coronary artery lesions caused by Kawasaki disease. Heart 2005; 91:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/108\">",
"      Kato H, Inoue O, Kawasaki T, et al. Adult coronary artery disease probably due to childhood Kawasaki disease. Lancet 1992; 340:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/109\">",
"      Tsuda E, Kitamura S, Kimura K, et al. Long-term patency of internal thoracic artery grafts for coronary artery stenosis due to Kawasaki disease: comparison of early with recent results in small children. Am Heart J 2007; 153:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/110\">",
"      Tsuda E, Kitamura S, Cooperative Study Group of Japan. National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan. Circulation 2004; 110:II61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/111\">",
"      Kitamura S, Tsuda E, Kobayashi J, et al. Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawasaki disease. Circulation 2009; 120:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/112\">",
"      Akagi T. Interventions in Kawasaki disease. Pediatr Cardiol 2005; 26:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/113\">",
"      Muta H, Ishii M. Percutaneous coronary intervention versus coronary artery bypass grafting for stenotic lesions after Kawasaki disease. J Pediatr 2010; 157:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/114\">",
"      Ishii M, Ueno T, Akagi T, et al. Guidelines for catheter intervention in coronary artery lesion in Kawasaki disease. Pediatr Int 2001; 43:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/115\">",
"      Guidelines for treatment and management of cardiovascular sequelae in Kawasaki disease. Subcommittee of Cardiovascular Sequelae, Subcommittee of Surgical Treatment, Kawasaki Disease Research Committee. Heart Vessels 1987; 3:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/116\">",
"      Checchia PA, Pahl E, Shaddy RE, Shulman ST. Cardiac transplantation for Kawasaki disease. Pediatrics 1997; 100:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/117\">",
"      Gersony WM. The adult after kawasaki disease the risks for late coronary events. J Am Coll Cardiol 2009; 54:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/6/30826/abstract/118\">",
"      Graham TP Jr, Driscoll DJ, Gersony WM, et al. Task Force 2: congenital heart disease. J Am Coll Cardiol 2005; 45:1326.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5772 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30826=[""].join("\n");
var outline_f30_6_30826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H242699421\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13231710\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13231717\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13231724\">",
"      CARDIOVASCULAR MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H242696497\">",
"      CARDIOVASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242696532\">",
"      Coronary artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H242698581\">",
"      - Natural course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242697570\">",
"      Myocardial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242698055\">",
"      Valvular regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242698174\">",
"      Pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242697681\">",
"      Noncoronary vascular involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242699572\">",
"      Long-term complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H329966460\">",
"      - Risk for atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H329966476\">",
"      - Myocardial function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H242696505\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13231738\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13231745\">",
"      Other noninvasive tests to image coronary artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242698454\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13231752\">",
"      Stress testing for inducible ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13231759\">",
"      Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H242698963\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13231780\">",
"      Prevention of coronary thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13231787\">",
"      Myocardial infarction and coronary thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13231794\">",
"      Coronary revascularization procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13231801\">",
"      Cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13231815\">",
"      LONG-TERM FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H329969197\">",
"      Participation in competitive sports",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H242699421\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13235158\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5772|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?0/45/726\" title=\"algorithm 1\">",
"      NHLBI pediatric risk stratification associated with CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/0/22543\" title=\"algorithm 2\">",
"      Dx incomplete KD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5772|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/53/4959\" title=\"figure 1\">",
"      Dimensions coronary arteries for children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/51/29489\" title=\"figure 2\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5772|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?35/29/36318\" title=\"movie 1\">",
"      Ascending aorta in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?18/43/19134\" title=\"movie 2\">",
"      Left coronary artery in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?16/54/17262\" title=\"movie 3\">",
"      Right coronary artery in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5772|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/25/44444\" title=\"table 1\">",
"      Risk stratification KD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/281?source=related_link\">",
"      Definition and screening for dyslipidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11814?source=related_link\">",
"      Incomplete (atypical) Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16183?source=related_link\">",
"      Kawasaki disease: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42025?source=related_link\">",
"      Kawasaki disease: Initial treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1882?source=related_link\">",
"      Management of pregnant women with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/40/14986?source=related_link\">",
"      Management of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/59/7098?source=related_link\">",
"      Overview of the non-acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/8/3201?source=related_link\">",
"      Patient information: Kawasaki disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25352?source=related_link\">",
"      Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40775?source=related_link\">",
"      Treatment of refractory Kawasaki disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_6_30827="fFN and risk of preterm birth";
var content_f30_6_30827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fetal fibronectin as a predictor for delivery within 7 and 14 days after sampling, combined results",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Study group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Delivery &lt;7 days",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Delivery &lt;14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Sensitivity (percent), 95 percent CI",
"       </td>",
"       <td class=\"subtitle2\">",
"        Specificity (percent), 95 percent CI",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sensitivity (percent), 95 percent CI",
"       </td>",
"       <td class=\"subtitle2\">",
"        Specificity (percent), 95 percent CI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All studies",
"       </td>",
"       <td>",
"        71 (57-84)",
"       </td>",
"       <td>",
"        89 (84-93)",
"       </td>",
"       <td>",
"        67 (51-82)",
"       </td>",
"       <td>",
"        89 (85-94)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women with preterm labor",
"       </td>",
"       <td>",
"        77 (67-88)",
"       </td>",
"       <td>",
"        87 (84-91)",
"       </td>",
"       <td>",
"        74 (67-82)&bull;",
"       </td>",
"       <td>",
"        87 (83-92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic (low risk or high-risk) women",
"       </td>",
"       <td>",
"        63 (26-90)*",
"       </td>",
"       <td>",
"        97 (97-98)",
"       </td>",
"       <td>",
"        51 (33-70)&bull;",
"       </td>",
"       <td>",
"        96 (92-100)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CI: confidence interval.",
"     <br>",
"      * Only one study included in analysis.",
"      <br>",
"       &bull; Fixed-effects model used (homogeneity test P &gt;0.10).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Leitich, H, Kaider, A. Fetal fibronectin - how useful is it in the prediction of preterm birth? BJOG 2003; 110 (Suppl 20):66.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30827=[""].join("\n");
var outline_f30_6_30827=null;
var title_f30_6_30828="Tx autoimmune hepatitis";
var content_f30_6_30828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment regimens for autoimmune hepatitis in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Prednisone only*, mg/day",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Combination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Prednisone*, mg/day",
"       </td>",
"       <td class=\"subtitle2\">",
"        Azathioprine",
"        <sup>",
"         &bull;",
"        </sup>",
"        , mg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Week 1",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Week 2",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Week 3",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Week 4",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintenance until end point",
"       </td>",
"       <td>",
"        20",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Reasons for preference:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Cytopenia",
"       </td>",
"       <td colspan=\"2\">",
"        Postmenopausal state",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiopurine methyltransferase deficiency",
"       </td>",
"       <td colspan=\"2\">",
"        Osteoporosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"       <td colspan=\"2\">",
"        Brittle diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td colspan=\"2\">",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short course (&le;6 months)",
"       </td>",
"       <td colspan=\"2\">",
"        Acne",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        Emotional lability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Hypertension",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Prednisolone can be used in place of prednisone in equivalent doses.",
"     <br>",
"      &bull; In Europe, a dose of 1 to 2 mg/kg/day is often used.",
"      <br>",
"       &Delta; Prednisone may be further tapered to an individual dose that maintains remission. 10 mg/day maintenance may be achieved by tapering the dose by 5 mg every week. A maintenance dose of 5 mg/day may be considered; in that case the&nbsp;dose is tapered by 2.5 mg every week. The maintenance prednisone regimen is continued until resolution of the disease, treatment failure, or drug-intolerance.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30828=[""].join("\n");
var outline_f30_6_30828=null;
var title_f30_6_30829="Ig light chain gene rearrangement";
var content_f30_6_30829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ig light chain gene rearrangement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 241px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Bona, C, Bonilla, FA. Textbook of Immunology, 2nd ed. Harwood Academic Publishers GmbH, Amsterdam 1996. Copyright &copy; 1996 Overseas Publishers Association, N.V. Permission granted by Gordon and Breach Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30829=[""].join("\n");
var outline_f30_6_30829=null;
var title_f30_6_30830="Modified FOLFOX6 plus bevacizumab chemotherapy";
var content_f30_6_30830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified FOLFOX6 plus bevacizumab chemotherapy for advanced colorectal cancer",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 14 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bevacizumab",
"        </strong>",
"       </td>",
"       <td>",
"        5 mg/kg IV",
"       </td>",
"       <td>",
"        Dilute into a total volume of 100 mL normal saline (NS)*. Administer first dose over 90 minutes following oxaliplatin and leucovorin. If well tolerated, the second infusion may be administered over 60 minutes after chemotherapy. If well tolerated, all subsequent doses may be administered over 10 to 30 minutes before chemotherapy",
"        <sup>",
"         &Delta;[3,4]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxaliplatin",
"        </strong>",
"       </td>",
"       <td>",
"        85 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Dilute with 250 mL 5 percent dextrose in water (D5W)* and administer over two hours (on days 1 and 15, oxaliplatin and leucovorin can be administered concurrently in separate bags using a Y-connector).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        Dilute with 250 mL D5W* and administer over two hours, concurrent with oxaliplatin.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV bolus",
"       </td>",
"       <td>",
"        Slow IV push over five minutes (administer immediately after leucovorin).",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        2400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU IV bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Oxaliplatin and FU are classified as irritants, but oxaliplatin can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors not justified (estimated risk of febrile neutropenia &lt;5 percent",
"        <sup>",
"         [2]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of oxaliplatin may be needed for severe renal impairment",
"        <sup>",
"         [5]",
"        </sup>",
"        . A lower starting dose of FU may be needed for patients with liver impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Maneuvers to prevent neurotoxicity:",
"        </strong>",
"        Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in blood pressure, urine protein concentration, neurologic function, and risk for bleeding prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment cycle one week for total white blood cell count &lt;3000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , absolute neutrophil count &lt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or platelets &lt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        on the day of treatment. If treatment is delayed for two weeks or delayed for one week on two separate occasions, eliminate FU bolus. With the second occurrence, reduce the infusional FU by 20 percent and the dose of oxaliplatin from 85 to 65 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        For transient grade 3 paresthesias/dysesthesias or grade 2 symptoms lasting longer than seven days, decrease oxaliplatin dose by 25 percent. Discontinue oxaliplatin for grade 4 or persistent grade 3 paresthesia/dysesthesia",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold FU for grade 2 or worse diarrhea, and restart at a lower dose after complete resolution",
"        <sup>",
"         [6]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicities:",
"        </strong>",
"        Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS)",
"        <sup>",
"         [3]",
"        </sup>",
"        . Do not administer bevacizumab within 28 days of surgery; suspend prior to elective surgery. Refer to UpToDate topics on \"",
"        <span class=\"emphasis\">",
"         Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\" and \"",
"         <span class=\"emphasis\">",
"          Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\".",
"         </span>",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     &Delta; For the 5 mg/kg dose, many clinicians administer the first dose over 60 minutes and if well tolerated, subsequent doses are administered over 10 minutes",
"     <sup>",
"      [4]",
"     </sup>",
"     .",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Many centers routinely infuse oxaliplatin through a central venous line because of local pain with infusion into a peripheral vein.",
"     <br/>",
"     &sect; Leucovorin dose is given for d,l-racemic mixture",
"     <sup>",
"      [7]",
"     </sup>",
"     . Use half the dose for LEVOleucovorin (l-leucovorin).",
"     <br/>",
"     &yen; The dose of leucovorin in the two trials of modified FOLFOX6 was 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . However, most clinicians use the standard 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     doses as was used for original FOLFOX6",
"     <sup>",
"      [8]",
"     </sup>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Cheeseman SL, et al. Br J Cancer 2002; 87:393.",
"      </li>",
"      <li>",
"       Hochster HS, et al. J Clin Oncol 2008; 26:3523.",
"      </li>",
"      <li>",
"       Avastin (bevacizumab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Reidy DL, et al. J Clin Oncol 2007; 25:2691.",
"      </li>",
"      <li>",
"       Eloxatin (oxaliplatin) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 13, 2011).",
"      </li>",
"      <li>",
"       Tournigand C, et al. J Clin Oncol 2004; 22:229.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30830=[""].join("\n");
var outline_f30_6_30830=null;
var title_f30_6_30831="Medullary thyroid carcinoma FNA";
var content_f30_6_30831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56242&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medullary carcinoma of the thyroid: Findings on fine needle aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine needle aspirate with immunostaining for calcitonin in medullary carcinoma of the thyroid. The nuclei of the tumor cells are placed eccentrically, and are larger and more pleomorphic than those of normal follicular cells. Immunocytologic staining for calcitonin is positive (brown staining which is best seen at the arrow). The background contains many red cells that nonspecifically take up the stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_6_30831=[""].join("\n");
var outline_f30_6_30831=null;
